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Summary 
Human cytomegalovirus (HCMV) infection causes clinical symptoms in 
immunocompromised individuals such as transplantant recipients and AIDS patients. 
The virus is also responsible for severe complications in unborn children and young 
infants. The species specificity of HCMV prevents the direct study of mechanisms 
controlling the infection in animal models. Instead, the murine cytomegalovirus (MCMV) 
is used as a model system. Human and murine CMVs have large double-stranded DNA 
genomes, encoding nearly 170 genes. About 30% of the genes are committed to 
essential tasks of the virus. The remaining genes are involved in virus pathogenesis or 
host interaction and are dispensable for virus replication. The CMV genes are classified 
in gene families, based on sequence homology. 
In the present work, the function of two genes of the US22 gene family was 
analyzed. The MCMV genes m142 and m143 are the only members of this family that 
are essential for virus replication. These genes also differ from the remaining ten US22 
gene family members in that they lack 1 of 4 conserved sequence motifs that are 
characteristic of this family. The same conserved motif is missing in the HCMV US22 
family members TRS1 and IRS1, suggesting a possible functional homology.  
To demonstrate an essential role of m142 and m143, the genes were deleted 
from the MCMV genome, and the mutants were reconstituted on complementing cells. 
Infection of non-complementing cells with the deletion mutants did not result in virus 
replication. Virus growth was rescued by reinsertion of the corresponding genes. Cells 
infected with the viral deletion mutants synthesized reduced amounts of viral DNA, and 
viral late genes were not expressed. However, RNA analyses showed that late 
transcripts were present, excluding a role of m142 and m143 in regulation of gene 
transcription. Metabolic labelling experiments showed that total protein synthesis at late 
times postinfection was impaired in cells infected with deletion mutants. Moreover, the 
dsRNA-dependent protein kinase R (PKR) and its target protein, the translation initiation 
factor 2α (eIF2α) were phosphorylated in these cells. This suggested that the m142 and 
m143 are required for blocking the PKR-mediated shut-down of protein synthesis. 
Expression of the HCMV gene TRS1, a known inhibitor of PKR activation, rescued the 
replication of the deletion mutants, supporting the observation that m142 and m143 are 
required to inhibit this innate immune response of the host cell. 
Zusammenfassung  
 
Die Infektion mit dem humanen Cytomegalovirus (HCMV) kann bei 
immunsupprimierten Personen wie Transplantatempfängern oder AIDS Patienten, aber 
auch bei Neugeborenen klinische Symptome hervorrufen. Die Spezies-Spezifität des 
humanen CMV lässt keine Untersuchung viraler  Mechanismen im Tiermodell zu, jedoch 
steht mit dem murinen CMV (MCMV) ein geeignetes und verbreitetes Modell zur 
Verfügung. Beide CMVs besitzen große doppelsträngige DNA Genome, die ca. 170 
Gene beinhalten. Hiervon sind ca. 30% essentiell für die virale Replikation. Die anderen 
Gene sind für die Pathogenesse und Interaktion mit den Wirtszellen von Bedeutung. Die 
Gene des CMV werden auf Grund von Sequenzhomologien in Familien gruppiert. In der 
vorliegenden Arbeit wird die Funktion der Gene m142 und m143 des MCMV analysiert. 
Beide Gene sind die einzigen für die Virusreplikation essentiellen Mitglieder der US22 
Genfamilie. Darüber hinaus unterscheiden sie sich von den anderen 10 US22 
Mitgliedern darin, daß ihnen eine von vier konservierten Sequenzmotiven fehlt. Dieses 
fehlende Motiv kommt auch bei den HCMV US22 Mitgliedern TRS1 und IRS1 nicht vor, 
was einen möglichen Hinweis auf eine funktionelle Homologie gibt. 
Um die essentielle Rolle der m142 und m143 Gene zu belegen, wurden letztere 
aus dem MCMV Genom entfernt und die Virusmutanten auf komplimentierenden Zellen 
rekonstituiert. Die Infektion nicht komplimentierender Zellen mit den Virusmutanten 
erzeugte keine Infektion, konnte jedoch mit der Reinsertion der Gene wieder hergestellt 
werden. Infizierte Zellen, die mit den Virusmutanten infiziert wurden, produzierten 
geringere Mengen viraler DNA. Obwohl die Expression später viraler Gene nicht 
stattfand, konnten späte virale Transkripte nachgewiesen und somit eine Rolle von 
m142 und m143 bei der Regulation der viralen Transkription ausgeschlossen werden. In 
Experimenten, in denen Zellen metabolisch markiert wurden, wurde gezeigt, daß die 
Gesamtproteinsynthese zu späten Zeitpunkten nach Infektion mit den Virusmutanten 
gehemmt war. Des weiteren wurde eine Phosphorylierung der dsRNA-abhängigen 
Proteinkinase R (PKR) sowie des Zielproteins, des Translations Initiationsfaktors 2α 
(eIF2α), nachgewiesen. Dies läßt vermuten, daß m142 und m143 die PKR-vermittelte 
Stillegung der Proteinsynthese verhindern. Durch Expression des HCMV TRS1 Gens, 
einem bekannten Inhibitor der PKR-Aktivierung, konnte die Replikation der 
Virusmutanten wieder hergestellt werden. Dies unterstützt die Ansicht, daß m142 und 
m143 für die Inhibition  der Angeborenen Immunanwort der infizierten Wirtszelle 
erforderlich sind. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Introduction 
 
 
 
 
1 INTRODUCTION 
 
1.1 Cytomegalovirus infection 
 
Human cytomegalovirus (HCMV, family Herpesviridae, subfamily 
Betaherpesvirinae, genus Cytomegalovirus, species Human cytomegalovirus) is a 
common pathogen world wide. CMV spreads at an early age and infects a large 
majority of the population, nearly 60-80% are affected (Trincado et al., 2001). The 
prevalence of infection and age at initial acquisition of the virus vary according to the 
living circumstances. CMV is not highly contagious and requires direct contact with 
infectious material. In many cases, transmission from mother to foetus or newborn 
occurs during birth. The vertical mode of transmission plays an important role in 
maintaining CMV infection in the population. Clinical features of the infection vary 
according to the mode of transmission. The virus can cause severe damage to the 
central nervous system (CNS) in congenital infection. Hepatomegaly and 
pneumonitis are associated with CMV infection in young infants. 
HCMV is one of the most important opportunistic pathogens that complicate the 
care of immunocompromised patients. Infection may occur because of reactivation of 
latent virus (organ transplantant recipients), re-infection, or primary infection (HIV 
patients). The infection correlates with the degree of immunosupression. The most 
severe cases are found in patients with allogeneic transplantation or the acquired 
immunodeficiency syndrome (AIDS). CMV infection is generally asymptomatic in 
immunocompetent individuals but it can cause infectious mononucleosis and it has 
been associated with vascular diseases (Nerheim et al., 2004; Melnick et al., 1993). 
Immunocompromised patients can develop a multisystem disease that might be life-
threatening.  
Studies on HCMV pathogenesis are important to develop an effective therapy 
and prevention. Because of the strict species specificity, HCMV has never been 
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successfully introduced into another animal. Therefore closely related CMVs with 
rodent and primate hosts are used as model systems: murine, guinea pig, rat, and 
rhesus macaque cytomegalovirus. Murine CMV is the most widely studied infection 
model. Viral functions influencing appoptosis, cytokine activation, leukocyte 
recruitment, lymphocyte surveillance, and antibody recognition have been 
characterised in both human and murine CMV, and many have been observed to 
influence the outcome of infection in mice. Murine cytomegalovirus (MCMV) and 
HCMV share similar structural features and pathogenic properties. Both viruses 
cause acute or persistent latent infections, depending on the immune status of the 
host. The infection of mice with MCMV provides a useful model for studying CMV 
pathogenesis and the host immune response against cytomegalovirus agents 
(Hudson, et al., 1979; Ho, 1995). However, MCMV and HCMV have some biological 
differences, as transplacental transmission of MCMV has not been demonstrated, 
and mouse models of foetal infection involve direct inoculation of MCMV into the 
CNS or uterus (Tsutsui et al., 1993). 
 
1.2 CMV virion 
1.2.1 Virion components 
 
The cytomegalovirus virion consists of an 
icosahedral capsid and a 235 kb dsDNA genome, 
surrounded by a tegument, and enveloped with a lipid 
bilayer carrying various virus-encoded glycoproteins (Fig 
1). 
HCMV and MCMV have a linear double-stranded DNA 
genome. Unlike other DNA viruses, CMV contains two 
types of RNA. One is tightly packed with the DNA at the 
origin of replication (Prichard et al., 1998) and the other is located at the tegument, 
expressed after entry into the cell. The HCMV genome consists of two covalently 
linked segments: unique long and unique short (UL and US) region, flanked by 
repeated terminals b and c and inverted sequences b‘ and c‘ (Fig 2). The directly 
repeated sequence a is also present at the termini and in inverted orientation at the 
junction between UL and US. The genomes of other β−herpesviruses are linear and 
Fig. 1. CMV virion. 
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lack internal repeats. The MCMV genome consists of a single unique sequence with 
direct repeats at either end (Ebeling et al., 1983).  
 
UL a b  b‘   a‘ c‘ US c a 
HCMV genome
MCMV genome
Sequence analysis of HCMV revealed a high divergence rate among different 
strains. The consensus sequence representing wild type HCMV is based on data 
from several low passage strains as well as clinical isolates (Dolan et al., 2004). The 
complete MCMV sequence was done for the Smith strain, which consists of 230 kb 
and about 170 predicted genes. The genome is essentially colinear with HCMV over 
the central 180 000 bp. During evolution, duplications of viral genes occurred and 
formed families of ORFs, common for all β-herpesviruses. A typical feature of this 
subfamily is the high amino acid homology. The gene families are characterised by 
the presence of certain conserved motifs (Fig 3).  
Fig. 2. Genome organisation of HCMV and MCMV. 
 
 
Fig. 3. Genetic map of MCMV. The colours represent dofferent gene families. 
Genome analysis revealed that about 30% of the encoded genes are 
committed to essential tasks of replication (Mocarski., 2004). These are herpesvirus-
common genes, found in all characterised mammalian and avian herpesviruses 
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 4
(Davison et al., 2002). They form seven conserved blocks. The arrangement of the 
conserved sequences is unique to the β-herpesviruses (Fig 4).  
 
1 2 3 4 5 6 7
1 2 3 4 5 6 7
 
 
 
Fig. 4. Conserved sequence blocks in HCMV and MCMV. 
 
Although the analysis of individual genes in HCMV and MCMV is still 
incomplete, it is known that nearly 70 ORFs are dispensable for virus replication in 
cell culture. This fact indicates that a large number of viral genes are devoted to 
optimising virus growth, cell tropism and pathogenesis in the host. About 46 genes 
are predicted to be nonessential as a result of spontaneous deletion during 
passaging in cell culture. 
 
1.2.2 Virus replication 
 
During natural infection HCMV replicates in various cell types: epithelial, 
macrophages, monocytes, endothelial, differentiated fibroblasts, smooth muscle 
cells, neuron and hepatocyte cells. However, in cell culture it has a restricted host 
range, and only few cell lines support productive replication (Sinzger et al., 1995). 
HCMV was isolated and propagated on human foreskin fibroblasts, which were 
shown to be most productive. Undifferentiated, transformed or aneuploid cell are non-
permissive.  
The replication cycle begins with viral attachment and penetration. Initially, the 
virus interacts with heparan sulphate proteoglycan complexes on the cell surface via 
virus-encoded glycoprotein complex gM/gN and binds to the epithelial growth factor 
receptor (EGFR) through another virus-encoded glycoprotein gB (Wang et al., 2003). 
However, not all permissive cells express EGFR, suggesting an involvement of 
additional receptors, most likely other growth factor receptors. Ultimately, the virus 
fuses with the plasma membrane, depositing the virion particles in the cell cytoplasm. 
The heterotrimeric complexes gH/gL/gO and gB are required for membrane fusion. 
Additionally, cellular integrins are known to serve as co-receptors. They interact with 
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EGFR and synergise with signal pathways. On the other hand, the interaction of gB 
with certain β1-integrins plays a crucial role for the entry (Compton, 2003, 2004). 
 Viral entry results in activation of cellular metabolism. Several signalling 
pathways are affected, including Ca2+ homeostasis, activation of arachidonic acid 
and its metabolites (Fortunato et al., 2000). The same effect is observed when UV-
inactivated virus enters the cell, suggesting that structural components of the virus 
are responsible for activation during virus-cell contact and/or virus entry. Entry 
activates also cellular transcription factors – cfos/jun, myc, NF-kB, SP-1, mitogen 
activated protein kinases ERK1, ERK2 and p38 (Kowalik et al., 1993; Yurochko et al., 
1995; Boyle et al., 1999; Boldogh et al., 1991). The virus-induced changes alter the 
host cell gene transcription. Mostly these changes do not require virus gene 
expression (Browne 2001; Simmen et al., 2001). Activation of host cell functions 
upon HCMV infection is associated with progression of the cell cycle and optimisation 
of the environment for virus replication. 
 After entering the cell, virus replication starts supported by the cellular 
machinery. Transcription of viral genes is directed by host cell RNA polymerase II 
and the associated machinery. This process is regulated by virus-encoded 
transactivators that are able to modulate virus gene as well as host gene 
transcription. Viral gene transcription is initiated also by EGFR, which has a strong 
mitogenic activity. HCMV has two major loci that are subjected for transcriptional 
control. One is the ie1/ie2 region which encodes a family of regulatory proteins (major 
immediate early complex – MIE) from differentially spliced transcripts and uses one 
of the strongest enhancers among the mammalians. The other is a sequence 
upstream of the US3 gene. Both have repetitive sequences and binding sites for 
cellular transcriptional factors. They are subject to negative regulation via the virus-
encoded protein IE2 and host factors. Suppression occurs with progression of the 
infection and is an independent process from viral gene activation. Similarly, the 
MCMV IE3 regulates gene expression by activation of early promoters and is able to 
repress transcription from the MCMV MIE (Angulo et al., 2000). Several tegument 
proteins are involved in transcription initiation together with host factors. One of the 
abundant tegument proteins, UL82 is a general activator of MIE (Liu, et al., 1991, 
Baldick et al., 1997). Others cooperate with viral regulatory factors and act as co-
transcription activators, such as pp69 and TRS1/IRS1, to ensure expression of the 
viral genes. 
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CMV gene expression is temporally regulated and classified in three kinetic 
classes, depending on the time and sensitivity to different inhibitors (DNA, RNA and 
protein synthesis). The first genes expressed are immediate early (α) genes. They 
are independent of any newly synthesized viral proteins and some of them encode 
regulatory trans-acting factors. The next genes expressed are early (β) genes. They 
require the presence of functional IE products. Some β gene products encode 
proteins which have a role in DNA replication, DNA repair or immune evasion. The 
third kinetic class are the late (γ) genes. They are expressed after the onset of DNA 
replication. The products of late genes are involved in modulating immune responses 
(envelope glycoproteins) or have a structural role (capsid proteins). 
α genes. Immediate-early proteins are produced first and regulate the 
subsequent early protein synthesis, DNA replication, and late protein synthesis. Four 
regions of α gene expression have been mapped on the human CMV genome: 
ie1/ie2 (major immediate early complex, MIEP), UL36 and UL37, TRS1/IRS1 and 
US3. Five exons are encoded downstream of the MIEP. The first three exons are 
spliced to either exon 4, generating the ie1 transcript, or to exon 5, generating the ie2 
transcript. In HCMV, the ie1 transcript is translated into the acidic 72-kDa IE1 
phosphoprotein. The HCMV ie2 transcript gives rise to the 86-kDa IE2 
phosphoprotein. The corresponding IE transcripts of MCMV encode the 89-kDa 
acidic IE1 phosphoprotein pp89 (Keil et al., 1987) and the 88-kDa IE3 protein 
(Messerle et al., 1992). Both IE1 and IE2 are involved in regulation of viral genes 
expression. IE1 augments its own expression by positive autoregulation of the MIEP. 
It also has a costimulatory function in activation of early gene promoters and 
mediates the disruption of nuclear structures (promyelocytic leukaemia protein-PML-
associated nuclear bodies or nuclear domains ND10) to ensure an optimal 
environment for viral replication. The IE2 protein is a transactivator of early genes 
and also of heterologous viral and cellular genes. It governs late gene expression as 
well (Mocarski et al., 1996; Stenberg, 1996). IE2 down-regulates transcription from its 
own promoter by binding to the cis-repression signal (crs) target site near the 
transcription start site of ie1/ie2, thereby mediating autoregulation of its own 
expression (Lang and Stamminger, 1993; Macias and Stinski, 1993; Wu et al, 1993). 
Moreover, it was reported that IE2 has a role in immune evasion by blocking IFNβ 
expression (Taylor and Bresnahan, 2005, 2006). 
 6
  Introduction 
All studied animal CMVs have an analogous MIE locus, but they vary 
depending on the presence of additional α genes. Some ancillary α products 
contribute to the regulation of gene expression or have different roles. Two IE 
products, TRS1 and/or IRS1 have been shown in transient assays to cooperate with 
IE1 and IE2 proteins and activate the transcription of early gene promoters. Later 
studies have shown that these genes are involved in immune evasion and virus 
assembly. The immediate early gene US3 encodes differentially spliced products, 
which are endoplasmatic reticulum-resident and block egress of peptide-loaded MHC 
class I proteins, representing a very early mechanism of immune evasion (Ahn et al, 
1996, Jones and Muzithras, 1992 ). Another two IE gene products, UL36 and UL37 
are involved in blocking apoptosis. UL37 encodes a viral analogue of the cellular 
antiapoptotic protein Bcl2 which can inhibit the downstream caspase 9 pathway 
(Goldmacher, 1999, 2001). By conrast, the UL36 gene product inhibits apoptosis by 
blocking caspase 8 activation. The synergetic work of all α genes ensures effective 
productive replication as it triggers the expression of further viral genes. 
β genes. Early proteins are required for viral DNA synthesis, cleavage and 
packaging of viral genomes, and assembly of viral particles. Additionally, they have a 
role in maintaining an optimal environment for viral gene expression and DNA 
replication (McElroy et al., 2000). The products of genes UL112-UL113 regulate the 
expression of core replication genes. The replicative complex components, DNA 
polymerase, and the DNA processivity factor are encoded by the β genes UL54 and 
UL44, respectively. Early genes are involved also in immunomodulation. US11 
encodes a protein which down regulates the expression of antigen-presenting 
molecule MHC class I. This function contributes to the IE US3 gene product and 
ensures the virus to escape from the host cell immune response. Another early gene, 
UL4 encodes a glycoprotein which has role in transcriptional and posttranscriptional 
control. The most abundant transcripts β1.2 and β2.7 are thought to have regulatory 
function but their translated products have not been studied yet. 
γ genes. Late genes encode proteins involved in modulating the immune 
response or have a structural role. The UL99 product is a highly immunogenic 
glycoprotein that localizes near the capsid surface of the virion (Landini et al., 1987).  
The HCMV glycoprotein gB initiates the antiviral response by activation of the 
interferon regulatory factor 3 (IRF3) (Boehme et al., 2004). Another late gene 
 7
  Introduction 
product, glycoprotein H is a target for the complement-independent neutralizing 
antibodies (Rasmussen et al., 1984).  
After entering the cell, expression of viral proteins is triggered to ensure viral 
replication. DNA replication starts at early time after infection. The genome 
circularizes and starts a rolling-circle replication, producing concatamers at late 
times. This process involves viral and host factors. Replication starts at a single origin 
of replication (ori Lyt) site, located within the UL region. This position is conserved in 
all β-herpesviruses. The synthesis of DNA is directed by herpesvirus conserved 
proteins, and the replicative complex is translocated to subnuclear sites where 
transcription starts. The DNA to be packaged is cleaved into unit-length pieces and 
inserted into the preassembled capsids. 
The CMV-infected cell produces different types of virus particles. Non-infectious 
particles are empty capsids that have acquired an envelope. Dense bodies consist of 
tegument proteins and envelopes. The infectious virions have packaged DNA and an 
envelope derived from the nuclear or cytoplasmic membrane. Virus egress via 
exocytic vesicle transport results in release of mature progeny into the extra cellular 
space. 
 
1.3 Virus – host interaction 
1.3.1 CMV influence on the host cell 
 
The CMV infection induces metabolic and structural changes in the host cell 
that are optimal for viral gene expression, replication and virion morphogenesis as 
well as survival (Muranyi et al., 2002). Co-infection studies revealed the impact of 
HCMV on cellular metabolism. HSV-1 and adenovrius replication have been shown 
to be activated by HCMV infection (McPherson et al., 1985; Spector et al., 1986; 
Colberg-Poley, et al., 1979). The ability of HCMV to activate cellular genes was 
associated with chronical proliferative diseases, such as cancers: adenosarcoma, 
Kaposi Sarcoma (Spector, 1984; Rosenthal, 1993) and possible involvement in 
vascular disease (Epstein et al., 1996). During HCMV infection the normal expression 
of the cyclin-dependent kinases is disrupted, and the cell cycle is blocked before 
replication of the cellular DNA (Bresnahan et al., 1996; Dittmer and Mocarski, 1997; 
Salvant et al., 1998; Wiesbusch and Hagemeier, 2001). Microarray analyses 
 8
  Introduction 
provided useful tool to monitor the expression of all virus and host cell mRNAs. They 
showed that HCMV-infected cells have upregulated mRNA levels of genes coding 
proteins, which have a role in cell cycle progression (Challacombe et al., 2004). 
Another study reported a dysregulation of mRNAs encoding proteins that function 
during mitosis and associate with abnormal mitotic spindles during the late phase of 
infection (Hertel and Mocarski, 2004). The infection also inhibits the licensing of host 
cell DNA origins of replication by preventing the assembly of a pre-replication 
complex (Biswas et al., 2003; Wiebusch and Hagemeier , 2001). All these changes 
favour optimal viral replication and efficient viral gene expression. On the other hand, 
HCMV infection induces the expression of cellular RNAs encoding interferon-
responsive proteins and pro-inflammatory chemokines (Browne and Shenk, 2003). 
These changes represent the attempt of the host cell to respond to infection and 
combat replication and spreading of an invading virus. 
 
1.3.2 Detection of the invader by the host 
 
The earliest response to an invading virus is the innate immune response. A 
major player of the antiviral defence is interferon type I production. The interferon 
type I response consists of three phases: induction of IFNβ, signalling, and antiviral 
gene expression (Fig. 5). The first phase includes activation of the IFNβ promoter 
upon viral entry. There are two pathways leading to interferon (IFN) production: the 
classical and Toll-like receptor mediated pathway. 
The classical pathway represents type I IFN induction, it is activated by 
double-stranded RNA (dsRNA). The presence of dsRNA is typical not only for RNA 
viruses, DNA viruses can generate dsRNA during transcription as a result from 
intermediate structures consisting of opposing RNA transcripts. Viral dsRNA is 
detected by two intracellular helicases, RIG1 and MDA5. These proteins are 
expressed in many tissue types and function in parallel. Binding of dsRNA to the 
helicase domain induces conformational changes which transmit the signal to the 
nucleus. Several factors are involved in signal transduction. Helicases interact with 
the recently discovered protein IPS-1/MAVS (Kawai and Akira, 2006; Seth et al, 
2005) that localized at the mitochondrial outer membrane, activates NF-kB promoter 
and leads to indirect activation of IRF3 (Kawai and Akira, 2006). Other kinases, IKK 
and TANK-binding (TBK) kinase phosphorylate the transcription factor IRF3 
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(Fitzgerald et al., 2003). The IFN regulatory factor 3 (IRF3) is a constantly expressed 
cellular protein, which resides in the cytoplasm. The phosphorylated form 
homodimerizes and moves to the nucleus, where it activates the expression of 
IFNβ and IFNα in cooperation with the cellular transcription factors AP-1 and NF-kB. 
 Toll-like receptors (TLR) are ancient conserved pathogen receptors that 
activate signalling pathways leading to expression of antiviral genes and induction of 
inflammatory cytokines (Akira et al., 2001). The HCMV envelope glycoprotein gB is 
recognized by TLR 2. The signal is transmitted by several kinases which results in 
activation of IFNα and IFNβ promoters (Compton, 2003 and 2004). Activation of 
TLRs is viral replication-independent, indicating a host mechanism for very early 
detection of virus. 
 
Fig. 5. IFN α/β response upon viral infection. 
IFNβ 
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IFNAR
IFNα 
IFNβ 
ISGs 
Produced IFNβ stimulates the neighbouring cells by binding to type I IFN 
receptors and activates Janus kinase/signal transducer and activator of transcription 
(Jak/STAT) pathway to stimulate the expression IFN stimulated genes (ISGs). STAT 
proteins are latent transcription factors, which are activated by phosphorylation and 
bind IFN regulatory factor 9 (IRF9). The complex is translocated to the nucleus, 
where binds the promoter of ISGs. The Jak/STAT signalling induces the expression 
of a number of proteins, including IRF family protein, IRF7. This factor is activated 
after phosphorylation and forms heterodimers with IRF3 to stimulate the ISGs for 
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increased expression of IFNβ and IFNα that cannot be induced alone (Sato et al., 
2000). The gene products transcribed from ISGs include proteins with antiviral 
activity: protein kinase R (PKR), oligoadenylate synthase (OAS), and Mx proteins, 
which establish an antiviral state in the infected cell and define the third phase of the 
IFN response.  
The ISG products are effector proteins with antiviral activity. They have 
different characteristics and effects on the host. Mx proteins belong to the 
superfamily of dynamin-like GTPases. They were discovered as factors for genetic 
resistance to orthomyxoviruses in mice (Pavlovic et al.,1995). Mx proteins are 
expressed only upon activation of ISGs by IFNα/β through the Jak/STAT pathway 
(Dupuis et al., 2003). OAS and PKR are constitutively expressed antiviral proteins, 
maintained in a latent, inactive form. Basal levels are upregulated by IFNα/β or IFNγ, 
and both enzymes are critically activated by viral dsRNA. The OAS catalyses the 
synthesis of short oligonucleotides that activate the latent endoribonuclease RNAseL. 
The activated enzyme degradates both viral and cellular RNA, leading to viral 
inhibition (Zhou et al., 1997). PKR is a serine-threonine kinase which is activated by 
the presence of dsRNA. The following dimerization results in autophosphorylation, 
which leads to phosphorylation of the eukaryotic translation initiation factor eIF2α 
(Williams, 1999). The eukaryotic translational factor eIF2α is responsible for 
recruitment of the small ribosomal subunits during initiation of translation. The active 
form is non-phopshorylated. In presence of dsRNA, eIF2α is phosphorylated and 
translation initiation of cellular and viral mRNA is blocked. Additional proteins with 
antiviral activity are ISG20 (Espert et al., 2003), promyeloleukemia protein (Regad et 
al., 2001), P56 (Guo et al., 2000), RNA-specific adenosine deaminase 1 (ADAR1) 
(Samuel, 2001) and guanylate-binding protein 1 (GBP1) (Anderson et al., 1999). P56 
binds eIF3, thereby inhibiting viral and cellular protein synthesis (Hui et al., 2003). 
The others have not yet studied functions 
 
1.3.3 Virus escapes the host immune response 
 
Viral infection in immunocompetent organism is characterized by persistence 
and release of virus for long periods in the face of the host immune system. During 
evolution, CMV has developed various survival strategies to complete its replication 
successfully. A large part of the genome encodes proteins that modulate and mimic 
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the immune response at different times of the replication cycle. Both human and 
murine cytomegaloviruses have evolved mutliple mechanisms to escape different 
host responses including the IFN system, cytotoxic lymphocytes, cytokine activation 
and migration, susceptibility to apoptosis and antibody-mediated defence. A crucial 
step for the invading virus is to overcome innate immunity as it is the earliest 
response of the host to viral infection. 
CMV interference mechanisms target different stages of IFN production, 
signalling, and expression of antiviral proteins. HCMV was shown to block 
IFNβ induction by the phosphorylated tegument protein pp71 (Abate et al., 2004, 
Browne et al., 2003). Others suggested that IE2 can cooperate with pp65 and block 
IFNβ production (Taylor and Bresnahan, 2005). The signal transduction of interferon 
receptors to specific elements of responsive genes is inhibited by HCMV and MCMV 
at different points. The HCMV protein p48 and MCMV M27 block the STAT 
dimerization and subsequent expression of the antiviral proteins PKR, OAS, Mx and 
IRF7 (Khan et al., 2004). HCMV can inhibit IFNγ induction by degradation of Jak1 
(Miller et al., 2002). TRS1/IRS1 have been reported to bind dsRNA and prevent the 
activation of PKR and subsequent phosphorylation of the eukaryotic translational 
initiation factor eIF2α, therefore avoiding a global protein synthesis shut off (Hakki 
and Geballe, 2005). On the other hand, HCMV ensures its own translation by 
encoding a kinase mTOR which supports protein synthesis in the host cell 
(Kudchodkar et al., 2004). 
 
1.3.4 The MCMV US22 gene family members m142 and m143 
 
Immune evasion is an important for the virus to complete successful 
replication. The large genome of herpesviruses contains many genes devoted to 
counteracting the immune response. It is assumed that the conserved blocks 
preserve essential for the virus functions, one of which is immune evasion.  
The US22 gene family is unique for the betaherpesviruses. The family was first 
described in HCMV, it consists of hypothetical proteins that are characterized by the 
presence of three or four conserved motifs (Kouzarides et al., 1988; Nicholas and 
Martin, 1994). Consensus sequences for motifs I and II have been identified, they 
contain short stretches of hydrophobic and charged residues. Motif I differs between 
HCMV family members in the unique short (US) and unique long (UL) region 
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(Nicholas et al., 1996). M139 – m143 share the same motif as the HCMV US family 
members. Motifs III and IV are less well defined but have stretches of nonpolar 
residues (Kouzarides et al., 1988). Genes encoded by ORFs m139 to m141 contain 
all four of these motifs, whereas m142 and m143 lack motif II. In addition, m139, 
m140, m142 and m143 each have an acidic domain common to herpesvirus 
transcriptional activators and specifically to MCMV immediate early proteins 1 and 2 
(Cardin et al., 1995).  
 The US22 gene family members are clustered at the either end of the 
genome. The family consists of 12 members in each murine and human CMV, and 
11 in rat CMV. Most of the MCMV US22 genes do not have HCMV sequence 
homolgoues, suggesting that conserved motifs determine important functions for the 
virus, resulting in a possible functional homology of HCMV and MCMV family 
members. The US22 gene family members are transcribed with immediate early or 
early kinetics of expression. Although the function of many US22 family genes is 
unknown, their functions have clearly diverged during evolution. Some of the gene 
products function as transcriptional transactivators, others regulate cell tropism or 
inhibit apoptosis. 
The HCMV US22 gene is expressed at early times and 
specifies a nuclear/cytoplasmic protein of unknown function, 
secreted into the extracellular space (Mocarski, 1988). The 
UL36 and its homologue in MCMV, M36, encode a potent 
inhibitor of Fas-mediated apoptosis that involves caspase 8 
activation (Skaletskaya et al., 2001, Menard et al., 2003). Other 
members of the family are important for optimal viral replication. 
The MCMV gene M43 is necessary for efficient replication in 
several cell types in vitro (Menard et al., 2003) and in salivary 
glands in vivo (Xiao et al., 2000). M139, M140 and M141 
mediate efficient replication in macrophages (Cavanaugh et al., 
1996; Hanson et al., 1999b, 2001; Menard et al., 2003) and are 
required for viral replication in the spleen, but not in the liver in 
vivo (Hanson et al., 1999b, 2001).  
HCMV MCMV 
US22 m128 
US23 M23 
US24 M24 
US26 m25.2 
UL23 m139 
UL24 m140 
UL28 m141 
UL29 m25.1 
UL36 M36 
UL43 M43 
TRS1 m142 
IRS1 m143 
 
 
Table.1. US22 members 
Deletion of HCMV US22 family genes UL28, UL29, US23, US24 and US26 
results in attenuated growth in human fibroblasts (Dunn et al., 2003; Yu et al., 2003), 
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while UL24 deletion results in impairment of replication in human microvascular 
endothelial cell (Dunn et al., 2003). However TRS1/IRS1 and m142/m143 are the 
only members that lack the same conserved sequence, motif II, and are expressed at 
immediate-early times. Moreover, these four genes are the only members of US22 
gene family known to be essential for the virus replication. The common features 
between the human CMV TRS1/IRS1 and mouse CMV m142/m143 genes 
distinguish them from the other US22 family members and suggest a special function 
for the encoded proteins. 
The human CMV genes TRS1 and IRS1 include sequence from both repeated 
and unique segments of the genome. The N-terminal two thirds of pTRS1 is encoded 
in the c repeat region, and the remainder of the protein is coded within the unique 
short region. The related protein, pIRS1, is encoded in the internal c‘ region together 
with the adjacent unique short region (Fig 6).  
 
b‘a‘ c‘ c  a Us 
IRS1 TRS1  
 
 HCMV genome 
 
 Fig. 6. Schematic presentaion of TRS1 and IRS1 location in the HCMV genome.  
 
Consequently, the N-terminal domains of pTRS1 and pIRS1 are nearly 
identical, and the two proteins have different C-terminal domains (Wetso and Barrell, 
1986). Because their amino-terminal domains are encoded in the repeat region, the 
transcription of these genes is controlled by identical immediate early promoters. 
Both TRS1 and IRS1 are packaged into the virion, and therefore are delivered to the 
cell immediately upon infection (Romanowski et al., 1997). The first function ascribed 
to pTRS1 and pIRS1 was transcriptional activation. Both proteins were found to act in 
conjunction with the immediate early transcriptional regulatory proteins, IE1 and IE2, 
but not on their own, to increase expression from the UL44 promoter in transient 
transfection assays (Stasiak and Mocarski, 1992; Romanowski and Shenk 1997). 
Subsequent analyses identified TRS1/IRS1 as 1 of 11 loci that are required for 
transient complementation of HCMV DNA replication (Pari et al., 1993). In this assay, 
pTRS1 and pIRS1 likely facilitate the accumulation of the proteins that function 
directly in the replication process (Iskenderian et al., 1996). In addition, the products 
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of TRS1, but not IRS1 acts late during infection to facilitate the production of virions 
(Blankenship and Shenk, 2002, Adamo et al., 2004). Moreover, recently investigators 
reported that the US22 gene family members TRS1 and IRS1 can reverse the PKR-
mediated shut-off of protein synthesis, induced by a recombinant herpes simplex 
virus type 1 (HSV-1) lacking the γ134.5 gene (Cassady, 2005) and that TRS1 
possess dsRNA binding activity (Hakki and Geballe, 2005). Earlier studies have 
shown that TRS1 and IRS1 can rescue the replication of a vaccinia virus lacking the 
dsRNA-binding protein E3L (Child et al., 2004). 
The MCMV genes m142 and m143 were first identified as immediate early 
genes by Hanson and coworkers when analyzing transcripts from the HindIII-I region 
of the MCMV genome. It was before suggested that this region contains genes 
important for viral replication, since mutants with deleted genome from m137 to m141 
and m139 to m143 cannot grow on macrophages. Transcript mapping of the m142 to 
m144 region revealed that the transcripts derived from this region use a common 
polyadenylation signal downstream of m142 (Hanson et al., 1999). Further studies 
showed that disruption of m143 or ATG deletion of m142 impairs virus growth so that 
virus cannot be detected (Menard et al., 2003), indicating that m142 and m143 have 
an essential role for viral replication. 
 
1.4 Aim and tasks of the study 
 
The aim of the present work was to analyze the function of the murine 
cytomegalovirus genes m142 and m143. The basic approach applied in this work 
was the deletion of the viral genes m142 and m143 by targeted mutagenesis and 
functional analysis of the mutant viruses. The characterization of mutant viruses, 
lacking the genes m142 and m143 should reveal their role for virus replication. 
Analysis of viral gene expression at the protein level would demonstrate the 
importance of m142 and m143 for viral gene transcription. In an attempt to 
understand their role in the context of viral infection, the virus-host cell interaction and 
particularly the involvement of m142 and m143 in counteracting the antiviral immune 
response was investigated. In the light of existing knowledge, m142 and m143 were 
tested for functional homology with genes from other viruses. The MCMV genes 
m142 and m143 were compared with sequence homologues of HCMV, TRS1 and 
IRS1, which had previously been studied in more detail. The construction of mutant 
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MCMV genomes, in which m142 or m143 were deleted and TRS1 was inserted 
should answer the question whether these genes possess similar functions. 
The data obtained in the present work provides new insights into the functional 
role of the essential MCMV genes m142 and m143. 
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2. MATERIALS AND METHODS 
   
   
2.1. MATERIALS 
 
Table 2. Antibiotics 
 
 
Table 3. Antibodies 
 
Antibody  
 
Working 
dilution 
Supplier 
 Primary antibodies   
Mouse αIE1 (croma101) Monoclonal antibody 1:1000  S. Jonjic;  Univ. of Rijeka 
Mouse αE1 (croma103) Monoclonal antibody 1:1000 S. Jonjic;  Univ. of Rijeka 
Mouse αgB (2E8.21A) Ascites fluid 1:1000 L. Loh;  
Univ. of Saskatchewan  
Mouse αM44 (3B9.22A) Ascites fluid 1:2000 L. Loh;  
Univ. of Saskatchewan 
Mouse αHA (16B12) Monoclonal antibody 1:1000  WB 
1:500    IF 
Hiss Diagnostic 
Mouse αPKR (B-10) Monoclonal antibody 1:200 Santa Cruz 
Rabbit αphospho eIF2α Polyclonal antibody 1:750 Cell signaling 
Rabbit αtotal eIF2α Polyclonal antibody 1:750 Cell signaling 
Rat αHA (3F10) Monoclonal antibody 1:200 IF Roche Applied Science 
 Secondary antibodies   
Goat αmouse HRP coupled Polyclonal antibody 1:1000 Dako cytomation 
Goat αrabbit HRP coupled Polyclonal antibody 1:3000 Cell signaling 
Goat αrat Alexa Fluor 488  Polyclonal antibody 1:1000 Molecular probes 
Goat αmouse Alexa Fluor 594  Polyclonal antibody 1:250 Molecular probes 
Antibiotic Short name Producer Stock (mg/ml)  Working dilution 
Ampicillin Amp Roth 100  1:1000 
Chloramphenicol Cam Roth 37.5  1:2500 
Carbencillin Carb Roth 60  1:1000 
Geneticin G418 G418 Invitrogen 100  0.7% 
Kanamycin Kan Roth 100 1:2000 
Zeocin Zeo Invitrogen 100 1:4000  
  Materials and methods 
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Table 4. Bacteria and viruses 
 
 
 
Table 5. Cell lines 
 
NIH-3T3 Mouse embryonic fibroblasts (ATCC CRL-1658) 
10.1 Immortalized mouse embryo fibroblasts (Harvey and Levin, 1991) 
Phoenix 293T-derived packaging cell line for MoMuLV (Kinsella and Nolan,1996) 
 
Table 6. Enzymes 
 
 
 
 
Table 7. Plasmids 
 
Strain  Description 
E. Coli DH10B Preparation of plasmid DNA. 
E. Coli DY380 Original strain DH10B with defective λ prophage. The prophage encodes gam, exo and bet 
recombination genes, under control of temperature sensitive repressor (Lee et al., 2001).  
MCMV GFP 
HCMV AD169 
MCMV Smith strain (U68299) genome and GFP cloned in BAC (Brune et al., 2000, 2001). 
HCMV lab strain AD169 (X17403) cloned in BAC (Borst et al., 1999). 
DNAaseI 
Pfu DNA polymerase 
Klenow fragment 
Proteinase K (stock 20 mg/ml) 
Restriction endonucleases 
RNAaseA (stock 10 mg/ml) 
Shrimp alkaline phosphatase   
Taq DNA polymerase 
T4 DNA ligase 
Qiagen 
Fermentas 
Fermentas 
Fermentas 
Fermentas, New England Biolabs 
Roth 
Fermentas 
Fermentas 
Fermentas 
Plasmid Supplier Application 
pcDNA3 Invitrogen Cloning and expression of viral genes 
pLXSN Clontech Introducing viral genes into the cellular genome 
pLXRN Clontech Introducing viral genes into the cellular genome 
pBluescript II KS+ Stratagene Base for constructing different helper plasmids 
pReplacer  
(pBS kan-m0206-PPGK) 
I.Jurak and 
W.Brune 
Helper plasmid for homologous recombination 
 
pCP20 
 
P. Cherepanov 
 
Removal of FRT flanked sequence by FLP recombination 
pcDNA-M45HA W.Brune M45-EX probe 
pCI-E3L M.A. Garcia Donor for E3L gene 
pZEO4 W. Bresnahan Amplification of Zeo resistance gene 
   
  Materials and methods 
 19
Table 8. Oligonucleotides and primers 
 
 
Primer / oligo Sequence  
 A. Primers for cloning in pcDNA 3 
m142HA fw 
m142HA r 
5’- AAA GAA TTC CAC CAT GGA CGC CCT GTG CGC GGC – 3’ 
5’- AAA AA CTCGAG T CAA GCG TAG TCT GGG ACG TCG TAT GGG TA gtc gtc 
atc gtc ggc gtc cgc – 3’ 
m143HA fw 
m143HA r 
5’ – AAA GGA TCC ACC ATG TCT TGG GTG ACC GGA GAT – 3’  
5’–AAA GAA TTC AAG CGT AGT CTG GGA CGT CGT ATG GGT A cgc gtc ggt cgc 
tct ctc gtc–3’ 
TRS1HA fw 
TRS1HA r 
5’ – AAA GAA TTC CAC CAT GGC CCA GCG CAA CGG CAT GTC G – 3’ 
5’ – AAA CTC GAG TCA AGC GTA GTC TGG GAC GTC GTA TGG GTA TTG AGC 
ATT GTA ATG GTA GT – 3’ 
IRS1HA fw 
IRS1HA r 
 
5’ – AAA GAA TTC CAC CAT GGC CCA GCG CAA CGG CAT GTC G – 3’ 
5’ – AAA CTC GAG TCA AGC GTA GTC TGG GAC GTC GTA TGG GTA ATG ATG 
AAC GTG GTG AGG GG – 3’  
  
 B. Oligonucleotides for cloning in pBlueSript II KS+ 
o142 fw 
 
o142 r 
5’ – AAA AAT CTA GAG CG CCA CCC TTC TCC ACC CGT GTT CCC GCT GCC 
GCC CGT CGC CCT CGC CGA ATT CGA TAT CCT CGA GGT TAA C – 3’ 
5’ – AAA ATA TCG AAT TCA AGG GCC CCG GGG AGG GGA GGG GTT TAT GTG 
ATG GCG AGG CGA TGT ACC GTC CGT CCG GTT AAC CTC GAG – 3’  
o143 fw 
 
o143 r 
5’ – TGA ATG CGG CCG CGA GGT GGT TGC CTC GGC TCC GCT CCG CTT CGT 
CCG CCC GTC TCG TGC GCG GAT CCG TTA ACG AAT TCG – 3’  
5’ – TTT GTG ATA TCC ATG TCG TCA CAG GGG AAA ACC GCC CCG TCG TGG 
ACC TCG ACG AGG CGG CGA ATT CGT TAA CGG ATC CG – 3’ 
  
 C. Primers for deleting m142 and m143 
Zeo-m142 fw 
 
Zeo-m142 r 
 
5’ – GCG ACC ACC CTT CTC CAC CCG TGT TCC CGC TGC CGC CCGTCG CCC 
TCG CCG AAT TCA AGT CCT GCT CCT CCT CGG CCA – 3’ 
5’ – CTC GTC GAA CCG ACC TTC TCT CAT CAG CCA CCC CAG CTG GGA CGC 
GAA GTT GTT GAC AAT TAA TCA TCG GCA – 3’ 
Zeo-m143 fw 
 
Zeo-m143 r 
5’ – GAG GTG GTT GCC TCG GCT CCG CTC CGC TTC GTC CGC CCG TCT CGT 
GCG CGG AAT TCA AGT CCT GCT CCT CCT CGG CCA – 3’ 
5’ – GGA GGC ATT CGT GAC AAT CTC CCT CCG CCT CGG AGC GCA GGG AGC 
GCG GCT GTT GAC AAT TAA TCA TCG GCA – 3’ 
  
 D. Primers for RT-PCR (designed by Dr.Marcus Picard Maureau) 
18s rRNA  
gB 
gM 
M44 
MCK-2 
PM024/25-TTATGGTTCCTTTGGTCGCTCG-CACCGGGTTGGTTTTGATCTGA 
PMLC001/002-GCGATGTCCGAGTGTGTCAAG-CGACCAGCGGTCTCGAATAAC 
PMLC003/004-TGCTTCGTGAACATCGTGGTG-GATCGCGTTGTACATCGTCAGG 
PMLC007/008-TGCACCAGGCGCTCTGTAAC-CGCTGAGGAAGTTCTCGATGG 
PMLC011/012-GTGTCTGGTCAGATCTCGGTC-CATCGGCCACGTACATCATG 
  
 E. Additional primers for sequencing 
m142 rev-i 
m142 fw-i   
m143  F1 
TRS1 F1 
TRS1 F2 
TRS1 F3 
3’ –  ATCGT GCCGCGGTCC AGACGC – 5’ 
5’ –  ACCG  AGG  AGCTGAGATGGTT – 3’ 
5’ –  AAG CAG GAG ACC AAC CCC CTG – 3’  
5’ – CGG ACC TGC GTC AAC TGT – 3’  
5’ – GTG CGT CGG CAC CTG AAC – 3’  
5’ – TGC TGG TGG TGC TGC TGG – 3’ 
*The letters in italic indicate restriction sites, HA-sequence is underlined. 
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Table 9. Kit sets 
 
 
Table 10. Size markers 
 
 
 
 
 
  
 
Table 11. Solutions and buffers 
 
 
NucleoBond PC100  
NucleoBond PC500 
NucleoSpin Plasmid 
 
NucleoSpinExtract II 
NucleoTrap 
 
RNeasy Mini kit (50 preps) 
RT Superscript II kit 
SYBER Green Fast Master mix  
 
BigDye Terminator ver 3.1 
 
DIG High Prime Labeling kit 
 
Macherey Nagel 
Macherey Nagel 
Macherey Nagel 
 
Macherey Nagel 
Macherey Nagel 
 
Qiagen 
Invitrogen 
Roche 
 
Applied Biosystems 
 
Roche 
 
 
DNA Midi prep (plasmid, BAC) 
DNA Maxi prep (plasmid) 
DNA Mini (plasmid) 
 
Agarose gel extraction; enzyme, salt or 
unincorporated dd NTPs (sequencing, SB) 
removal 
RNA column purification 
Reverse transcription of RNA 
cDNA amplification for real time PCR 
 
Cycle sequencing reaction 
 
Southern blot 
DNA ladder 1kb Fermentas 
Genomic DNA marker  Fermentas 
RNP800  Rainbow marker Amersham 
A. Plasmid DNA prep  
Solution 1 (S1) 50 mM Tris/ HCl, 10 mM EDTA 
Solution 2 (S2) 200 mM NaOH, 1% SDS 
Solution 3 (S3) 2.8 M Potassium Acetate pH 5.1 (CH3COOH) 
TE buffer 10 mM Tris/ HCl, 1mM EDTA pH 7.8 (NaOH) 
B. Total DNA preparation  
PK buffer 100 mM Tris, pH 8.0; 5 mM EDTA; 0.2% SDS; Sodium chloride 200 mM 
50x TAE 242 g Tris, 57.1 ml conc. Acetic acid, 100 ml 0.5 M EDTA in 1L H2O 
10x TBE 108 g TRIS, 55 g Boric Acid, 40 ml EDTA (0,5M) in 1L water   
C. RNA preparation  
10x MOPS 
 
1x Running buffer 
 
5x loading dye 
0.2M MOPS, 50mM Sodium acetate, 10mM EDTA, DEPC water 
 
100 ml 1xMOPS, 20ml formaldehyde (37%), 880ml DEPC water 
 
16μl saturated bromphenolblue, 8 μl 0.5M EDTA, 72 μl formaldehyde (37%), 
200 μl glycerol, 308 μl formamide, 400 μl 10xMOPS, 4 μl DEPC water 
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D. Protein analysis  
RIPA lysis buffer 20mM Tris/HCl, pH 7.5; 300mM NaCl; 1% Na-Deoxycholat;  
1% Titon X-100; 0.1% SDS 
Triton lysis buffer 10mM Tris/HCL, pH 8.0; 140mM NaCl; 0.025 NaN3; 1% Triton X-100 
TRICINE buffer 3M Tris/HCL pH 8.5; 0.3% SDS 
Loading buffer (2xPPP) 125mM Tris/HCl, pH6.8; 4% SDS; 20% Glycerol;  
10% 2-mercaptoethanol; 0.05% bromphenol blue 
5x Cathode buffer 0.5M Tris; 0.5M Tricine; 0.5% SDS  
10x Anode buffer 2M Tris/HCl pH 8.9 
Transfer buffer 3.0g Glycine; 6.0g Tris; 400 μL SDS; 200ml Methanol 
10xTBS 100mM Tris-HCl, pH 8.0; 1.5M NaCl 
Blocking reagent 5% Milk in 1x PBS;  3% Milk in 1xTBS; 4% BSA in 1xTBS 
Antibody incubation 5% Milk in 1x PBS; 4% BSA in 1xTBS and 0.1 Tween20, 1,5% Milk in 1xTBS 
and 0.5%Tween20 
Washing buffers 1xPBS-0.5% Tween20; 1XTBS-0.5% Tween20 
E. Southern blot   
Fragmentation solution 0.25N HCL 
Denaturing buffer 0.5M NaOH; 1.5M NaCl 
Neutralising buffer 0.5M Tris pH 7.0; 1.5M NaCl 
20x sodium chloride/sodium 
citrate buffer (SSC) 
3M NaCl; 0.3M Na Acetate 
Maleic Acid buffer 0.1M Maleic Acid; 0.15M NaCl, pH 7.5 (solid NaOH) 
Washing buffer 0.1M Maleic Acid; 0.15M NaCl, pH 7.5 (solid NaOH); 0.3% Tween 20 
Washing buffer 1 2xSSC, 0.1% SDS  
Washing buffer 2 0,5xSSC, 0.1 % SDS  
Detection buffer 0.1M Tris/HCL; 0.1M NaCl, pH 9.5 
F. Transfection of Phoenix cells 
(Calcium phosphate coprecipitation) 
 
Na2HPO4 dibasic stock solution 5.2g in 500ml water 
2xHBS 8.0g NaCl, 6.5g HEPES, 10ml Na2HPO4 stock, pH to 7.0 
(NaOH), up to 500 ml water 
CaCl2 2M  
Chloroquine 50mM 
  Materials and methods 
 22
 
 
 
 
Table 12. Reagents and chemicals 
 
 
 
 
 
G. Immunofluorescence   
Fixative solution  For 100ml solution: 4g  paraformaldehyde; 1M NaOH; 10ml 10xPBS 
Ammonium chloride Dissolve 267mg NH4Cl in 100ml 1xPBS 
Permeabilizing solution 0.3% Triton X-100 
Blocking solution 0.2% gelatin in 1xPBS 
Washing buffer 0.1% Tween 20; 1x PBS 
DAPI staining 250 μg/ml final concentration   
Propidium iodide staining 1.0 μg/ml final concentration 
A. Color reagents  
Bromphenolblue Na Salt 
4'-6-Diamidino-2-phenylindole (DAPI)  
Ethidium bromide  
Orange G  
Propidium iodide  
Roth 
Roth 
Roth 
Roth 
Roth 
B. Medium and serum  
LB – Broth (Lennox) 
Dulbecco's Modified Eagle Medium (DMEM) 
L-Glutamine 200mM (100x) 
Fetal Calf Serum (FCS) 
Newborn Calf Serum (NCS) 
Penicillin/Streptomycin (100x) 
Trypsin – EDTA 1x 
Redivue PRO – MIX – L(35S) in vitro Labelling Mix 
RPMI without L – Cys, L – Glu, L – Met 
 
Roth 
PAN Biotech 
Gibco (Invitrogen) 
PAN Biotech 
PAN Biotech 
PAN Biotech 
PAN Biotech 
Amersham, Biosciences 
PAN Biotech 
 
C. Reagents   
Aqua polymount 
Diethylpyrocarbonat (DEPC) 
Hexadimethrine bromide  (Polybrene) 
phenol/ chlorophorm/ isoamyl alcohol (PCI) 
Protease inhibitor cocktail `Complete Mini` 
Polyfect 
Superfect 
TRIzol  
Polyscience Inc. 
Roth 
Sigma 
Roth 
Roche Diagnostics 
Qiagen 
Qiagen 
Invitrogen  
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D. Chemicals  
 
Absolute ethanol 
Agar-agar 
Agarose 
Ammonium persulphate 
Ammonium chloride 
2- mercaptoethanol 
Boric acid 
Calcium chloride 
Chlorophorm  
Dimethylsulfoxide 
Dithiothreitol (DTT) 
Phosphate-buffered saline (PBS) 
Ethilenediaminetetraacetic acid (EDTA) 
Ethanol 
Formaldehyde 37% 
Formamide 
Gelatine 
Glacial acetic acid 
Glycin 
Glycerol 86% 
HEPES (sodium salt) 
Isopropanol 
Maleic acid 
Magnesiumchloride - hexahydrate 
Milk powder 
3-(N-morpholino)propanesulfonic acid (MOPS) 
Na Deoxycholate 
Na acetate 
N - (trishydroxymethil) methilglycine  (TRICINE) 
N,N,N’,N’, Thetramethylendiamine (TEMED) 
p-formaldehyde 
Salt acid (HCl) 37% 
Sodium acetate anhydrus 
Sodium dodecyl sulfate (SDS) 
Sodium hydroxide 
Sodium chloride 
Sodium hydrogen phosphate dibasic 
Triton X-100 
Tris base 
Tween 20 
 
Roth 
Roth 
Roth 
Roth 
Roth 
Roth 
Roth 
 
Roth 
Roth 
PAN Biotech 
Roth 
Roth 
Roth 
Roth  
Roth 
Sigma 
Roth 
Roth 
Roth 
Roth 
Roth 
AppliChem 
Merck 
(Market) 
AppliChem 
Roth 
Roth 
Roth 
Roth 
AppliChem 
Roth 
Roth 
Roth 
Roth 
Roth 
Roth 
Roth 
Roth 
Roth 
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Table 13. Instruments and support equipment 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Agarose gel chamber 
Blotting device for proteins 
Blotting set for DNA 
 
Centrifuge rotors 
 
Cover slips 
Confocal microscope 
Developing X-ray films 
Electroporator 
Electroporation cuvettes  
Fluorescent light microscope 
Gel dryer 
Quasishredder columns 
Hybridization chamber 
Inverted light microscope 
Incubators  
 
Phaselock tubes Heavy (PLG) 
Photodocumentation system 
Pipettes  
Plastic for cell culture 
Polyacrilamide gel system 
 
Radiographic cassette 
 
Shakers  
 
 
Spectrophotometer   
Sterile bench 
Thermal cycler 
Transfer membrane for proteins 
Transfer membrane for DNA 
 
Vortex  
UV crosslinker 
 
Amersham Bioscience, Biometra, Peque Lab 
Fast blot B34, Biometra 
TurboBlotter, Schleicher&Schuell 
Slot blot device, Roth  
5415 R, 5415D, 5810 R; Eppendorf 
Avanti J20XP, JA25-15, JA25-50, JLA16-250 , Beckmann Coulter   
1.5 mm, round, Cubre-objectos, Hartenstein 
Zeiss Axioplan, model LSM 510, Oberkochen, Germany 
X-Ray Retina, Kodak  
MicroPulser Electroporator Apparatus, Biorad  
2 mm, Biorad 
Zeiss 
Bio Rad 
Qiagen 
HB-100 Hybridizer, Biometra 
Zeiss  
Bacterial incubator M100, Memmert 
CO2 Incubator, HERA Cell240 
Eppendorf 
E.A.S.Y.  Win32, Herolab 
Gilson, Labsystem 
Greiner, Nunc, Sarstedt 
Hoefer HF 99X (15x20 cm), Amersham Bioscience 
Mini Protean 3 Cell (7x8 cm), BIO RAD 
Dr.GoosSuprema 
 
Incubator shaker ISF1, Kuehner 
Thermomixer comfort, Eppendorf 
Shaker 3013, GFL Burgwedel 
Eppendorf; NanoDrop, Peque Lab 
Laminar-Flow, HeraSafe, BDK Sonnenbuehl-Genkingen 
Gene Amp 9700, Applied Biosystems 
Hybond ECL Nitrocellulose, Amersham Bioscience 
NytranSuperCharge Nylon, Schleicher&Schuell 
Roti-Nylon, Roth 
Vortex-genie 2, Scientific Ind. 
Stratagene 
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2.2. METHODS 
 
 
 
2.2.1. Molecular biology methods 
 
 
2.2.1.1. Cloning  
 
 
Gene amplification for cloning in expression vectors and homologous 
recombination 
 
The genes m142 and m143 were amplified from the MCMV-GFP BAC, and TRS1 
and IRS1 from the HCMV AD169 laboratory strain. Primers have included HA tag 
sequence at the 3´end, they are listed in Table 8A.  
 
The following master mixtures were prepared (1x): 
 
 
A. for cloning of m142 and m143, final volume 50 μl: 
 
1.0 μl   Template DNA (MCMV GFP BAC) 1.6 μg/μl 
2.0 μl   dNTP 10 mM 
2 x 1.0 μl  primers 10 pmol/ μl (stock solution 100 pmol/ μl)   
5.0 μl   10x Buffer (with MgSO4)   
1.0 μl   Pfu polymerase (5U/ μl)  
39.0 μl  dH2O 
 
B. for cloning TRS1 and IRS1: 
 
1.0 μl   Template DNA (HCMV GFP BAC) 1.6 μg/μl 
2.0 μl   dNTP 10 mM 
2 x 2.0 μl  primers 10 pmol/ μl (stock solution 100 pmol/ μl)   
5.0 μl   10x Buffer (w/o Mg)   
3.0 μl   25mM Mg++   
Taq + Pfu 1:1  
 
Up to 50 μl dH2O 
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C. Amplification of the zeocin resistance gene with different homologous arms (zeo –
m142, zeo – m143, zeo – m142/143): 
 
 
D. Hybridisation reaction of synthetic oligonucleotides o142 and o143 
 
Components:  
25mM Mg++   10.0 μl 
Buffer    10.0 μl 
Taq polymerase     2.0 μl (2 units) 
dNTPs     4.0 μl 
Oligos 2x1.0 μl 
dH2O   72.0 μl 
Total volume 100.0 μl 
 
 
Amplification programs  
 
 
Initial denaturation    95°C    1 min 
 
Touch down   95°C /65°C /72°C 1 min/30 sec/90 min 10 cycles, annealing step -1° 
(at 72°C: 150 min for TRS1 and IRS1, 30 sec for zeo cassette)  
 
Amplification   95°C /55°C /72°C      1 min/30 sec/90 min  35 cycles 
 
 
 
Hybridization reaction for synthetic oligos: 
 
Denaturation   94°C  2 min 
 
Annealing (oligo m143)  54°C 30 sec 
  (oligo m142)  50°C 30 sec 
 
Synthesis   72°C  5 min 
 
10.0 μl   Template (pZEO4)   
10.0 μl   10mM dNTPs 
2x1.0 μl 10pmol/μl Primers 
25.0   μl   Buffer 
  1.0   μl   Taq polymerase 
194.0 μl   dH2O  
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Digestions 
 
DpnI digestion 
The PCR fragments zeo-m142, zeo-m143, zeo-m142/m143, m142HA, m143HA and 
TRS1HA were purified from the bacterial DANN by digestion with DpnI, which 
recognizes methylated bacterial DNA. The following mixture was set: 
 
PCR product 45 μl 
DpnI    3 μl 
Buffer Y+ 20 μl 
dH2O          132 μl (up to 200μl) 
 
The reaction was incubated for 2 hours at 37°C. 
 
 
Endonuclease restriction digestion 
A. For cloning in an expression plasmid, amplified fragments m142 HA, m143 HA, TRS1 
HA, IRS1 HA and vector molecules were digested with endonucleases as follows: 
 
 
 
Reactions were incubated at 37°C for 2 hours. 
 
Ligation products: pcDNAm142 HA, pcDNAm143HA, pcDNATRS1HA and pcDNA 
IRS1HA. 
 
B. Subsequently the HA genes m142, m143 and TRS1 were subcloned into retroviral 
plasmids pLXSN or pLXRN.  pcDNA constructs containing the corresponding genes and 
retroviral vectors were digested as follows: 
 
EcoRI   2.0 μl  EcoRI  2.0 μl EcoRI       2.0 μl EcoRI       2.0 μl 
XhoI   2.0 μl  XhoI  2.0 μl BamHI      2.0 μl BamHI      2.0 μl 
m142 HA 
TRS1 HA 
 IRS1 HA 
25.0 μl  pcDNA  2.0 μl m143HA 25.0 μl pcDNA 2.0 μl 
dH2O    7.0 μl  dH2O 30.0 μl dH2O 7.0 μl dH2O 30.0 μl 
Buffer   4.0 μl  Buffer   4.0 μl Buffer 4.0 μl Buffer 4.0 μl 
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Ligation products: pLXSN TRS1HA, pLXSN m142HA and pLXRN m143HA. 
  
C. For generating the helper plasmids, hybridized synthetic oligos were cloned into 
pBluescriptII KS+ with two consequent digestions:  
 
oligo m143 10.0 μL   pBS 3.0   
EcoRV  1.0 NotI   1.0 EcoRV 1.0 NotI 1.0 
Buffer R  3.0 Buffer O   5.0 Buffer R 3.0 Buffer O 5.0 
dH2O 16.0 dH2O 14.0 dH2O 23.0 dH2O 14.0 
vol. 30.0, 2h at 37°C vol. 50.0, ON at 37°C vol. 30.0, 2h at 37°C vol. 50.0, ON at 37°C 
 
Ligation products: pBSo142 and pBSo143. 
 
 
 Probes for southern and slot blot 
 
pcDNA constructs, containing m142, m143 and M45 were digested to prepare probes 
for southern and slot blot. 
 
 
m142 2.0 μl m143  2.0 μl TRS1 2.0 μl pLXSN 10.0 μl pLXRN 10.0 μl 
EcoRI 0.2 μl EcoRI  0.2 μl EcoRI 2.0 μl EcoRI 2.0  μl BamHI 0.2  μl 
XhoI 0.2 μl  BamHI  0.2 μl XhoI 2.0 μl  XhoI  2.0  μl HpaI 0.2  μl 
Buff 2.0 μl Buff  4.0 μl Buff 4.0 μl buff 4.0  μl 2x buff 4.0  μl 
dH2O 15.6 μl dH2O 13.6 μl dH2O 15.6μl dH2O 22.0 μl dH2O 5.6  μl 
oligo m142 10.0 μL  pBS 3.0   
Apa I 1.0 (10 U) XbaI 1.0 (10 U) ApaI 1.0 XbaI 1.0 
Buffer B 3.0 Buffer Y 5.0 Buffer B 3.0 Buffer Y 5.0 
dH2O 16.0 dH2O 14.0 dH2O 23.0 dH2O 14.0 
vol. 30.0, 2h at 37°C vol. 50.0, ON at 37°C vol. 30.0, 2h at 37°C  vol. 50.0, ON at 37°C 
DNA fragment 5.0 μl (5.0μg) pcDNAm142 pcDNAm143 pcDNA M45 
EX 
Endonuclease 
enzyme 
2.0  μl (20 U) EcoRI BamHI EcoRI 
Buffer 3.0 (1x) Eco72I XhoI XhoI 
dH2O Up to 30  μl Buffer 2xY Buffer G Buffer 2xY 
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Ligase reaction 
 
Digested and purified fragments were ligated into corresponding vectors. Insert 
and vector were added at a ratio of 5:1. Reactions were performed with 1U T4 ligase at 
16°C overnight or 4 hours at RT. 
 
DNA-end modifications  
 
In order to facilitate the cloning, different DNA end modifications were made. 
Blunt end cloning was applied when the multiple cloning sites did not allow another 
opportunity. Klenow reaction was performed to complete the sticky ends. To prevent re-
ligation of the blunt-ended vector, dephosphorylation of the fragments was done with 
Shrimp Alkaline Phosphatase (SAP). After enzyme inactivation, the fragments were 
separated in 0.8% agarose gel and purified with NucleoSpin Extract II or Nucleo Trap kit, 
depending on the fragment size. 
 
 
 
 
 
 
time for incubation: 10 min at 37° C time for incubation: 30 min at 37°C 
inactivation: 10 min at 70°C  inactivation: 15 min at 65°C 
 
 
Preparative agarose gel electrophoresis 
 
Digested fragments were separated in 0.8% agarose gel 1xTAE. The agarose 
was melted in a microwave oven and cooled down. Before casting 3.0 μl ethidium 
bromid was added. The polymerized gel was loaded with samples and a standard 
molecular weight marker (1kb DNA ladder). 
 
Digested DNA 30.0 μl 
SAP   1.0 μl 
Buffer R+ (red buffer)   2.0 μl 
dH2O 17.0 μl 
Digested DNA 30.0 μl 
Klenow fragment  0.2  μl 
10 mM dNTPs  1.0  μl 
Buffer O+  2.0  μl 
dH2O 16.8 μl 
Klenow reaction SAP treatment 
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Fragment extraction from agarose gel 
 
After separation, fragments were cut from the gel and extracted depending on the 
size of the fragment with a NucleoSpin ExtractII or a Nucleo Trap kit according to the 
manufacturer’s instructions. 
 
 
Bacteria transformation  
 
Ligation reactions were transformed into electrocompetent bacteria of strain E. coli 
DH10B. 
 
Preparation of standard electrocompetent cells DH10B 
Bacteria cultures were grown overnight at 37°C. On the next day they were diluted 1 : 
100 and grown untill OD600 of 0.4 to 0.6. Bacteria were incubated on ice for 10 min and 
washed two times with cold water and once with 10% glycerol. Resuspended in glycerol 
bacteria were used directly for electroporation or frozen in liquid nitrogen and stored at –
80°C. 
 
 
Transformation with ligated constructs 
For transformation of electrocompetent bacteria, 2.0 μl ligation reaction was mixed with 
38 μl bacteria and pulsed in a 2.0 mm cuvette at 2.5 kV. After pulsing, 600 μl medium 
was added and cells were recovered by shaking at 37°C for 90 min. Bacteria were 
plated on agar containing corresponding antibiotic for selection. 
 
Plasmid DNA preparation (buffers Table 11 A) 
High copy plasmids were extracted and purified according to the following protocols: 
 
Mini preps, expected yield about 2.5μg total DNA. (DNA for screening) 
DNA for screening was prepared from 2 ml overnight culture. Cultures were pelleted and 
supernatant removed. Bacteria were resuspended in S1 buffer and lyzed in S2 buffer. 
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DNA was separated from the dirt by incubation with S3 buffer and precipitated with 60% 
isopropanol. The pellet was washed in 70% ethanol and resolved in TE buffer containing 
RNAse (0.1μg/μl final concentration). 
  
Maxi preps, expected yield about 500 μg total DNA. (DNA for further analysis) 
Larger scale DNA was prepared and column purified with kit Nucleo bond PC500, (Maxi 
prep high copy plasmid protocol) according to the manufacturer’s instructions.  
 
Bacterial glycerol stocks 
Bacteria containing final constructs were stored frozen as glycerol stocks at –80°C. Sixty 
percent glycerol was mixed with 1 volume overnight large scale bacterial culture. 
 
 
2.2.1.2. Sequencing  
 
DNA quality. Primers  
The DNA for sequencing was column purified with a NucleoSpin Plasmid kit or prepared 
with Nucleo Bond PC100 kit. Genes cloned into expression vectors were sequenced 
using standard T7 and SP6 primers for pcDNA3 or T3 and M13 primers for pBluescriptII 
KS+.  
 
Cycle sequencing  
Sequencing reactions were performed with Big Dye Terminator Ready reaction mix ver. 
3.1 kit (BDT) and analyzed with an automated sequencer ABI Prism (Institute for 
Virology and Immunology, University of Würzburg). 
 
Sequencing reactions were prepared in 0.2 ml 8-strips. 1/8 th reaction mixture contains: 
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Cycle sequencing was performed using the thermal cycler Gene Amp 9600 : 
 
Initial denaturation    96°C    1 min 
cycle sequencing  96°C /55°C/60°C      20 sec/15 sec/4 min 25 cycles 
 
The products were subsequently column purified with Montage SEQ96 Sequencing 
reaction kit and analyzed with automated sequencer ABI 3100. 
 
2.2.1.3. Homologous recombination  
 
Homologous recombination was used to delete viral genes or insert fragments 
into the MCMV genome (Yu et al., 2000). 
 
Recombination in DY380 cells 
 
E.coli strain DY380 contains a λ prophage, which expresses recombinases under 
control of temperature sensitive repressor and BAC MCMV-GFP carrying 
chloramphenicol resistance gene. A PCR-generated linear fragment with 50 bp 
homologous arms was transformed into electrocompetent, induced DY380 bacteria.  
This methodology was used to create the deletion (Δm142, Δm143, Δm142/m143) 
and replacement/insertion mutants (TRS1Δm142, TRS1Δm143, E3L Δm142, 
E3L Δm143, IRS1 Δm142 and IRS1 Δm143; TRS1/o142, TRS1/o143, E3L/o142, 
E3L/o143). 
 
BDT 1.0 μl 
Primer (5 pmol/ μl) 1.0 μl 
2.5x buffer (200 mM TrisHCL, pH 9.0, 5mM 
MgCl2 ) 
1.0 μl 
DNA (plasmid DNA 50ng/ μl) 2.0 μl 
Total volume 5.0 μl 
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Induction of DY380 
Bacterial cultures were grown at 30°C overnight under selection with chloramphenicol. 
On the next day, they were diluted 1:100 and grown at 30°C up to an OD600 of 0.4 to 0.6. 
Cells were induced by incubation at 42°C for 10 min with intensive shaking and cooling 
on ice. Bacteria were prepared for electroporation by washing in cold water two times 
and once in 10% glycerol. Bacteria were resuspended in 10% glycerol and transformed 
immediately or frozen in liquid nitrogen and stored at -80°C. 
 
Transformation of linear fragment for recombination 
For transformation of DY380 cells, 5.0 μl purified fragment was mixed with 35 μl of 
competent cells. Bacteria were electroporated in a 2 mm cuvette with pulse at 2.5 kV. 
After pulsing, 600 μl fresh medium was added and bacteria were recovered by shaking 
at 30°C for 90 min. Transformed bacteria were plated on agar containing 
chloramphenicol and an additional antibiotic for selection.  
 
Arabinose-inducible recombination 
 
DH10B cells containing the MCMV-BAC, were transformed with a plasmid 
(pKD46) expressing recombinases upon induction with L-arabinose.  
For constructing revertant mutants, DH10B cells were transformed with BAC 
genomes of MCMV deletion mutants. These bacteria were made competent using a 
quick procedure. 4 ml cultures were pelleted, washed twice in cold water and once in 
10% glycerol. The bacteria were immediately transformed with an amp resistant plasmid 
pKD46. After recovery, they were plated on agar with selective antibiotic. Grown cultures 
were induced with 1mM L-arabinose and used to make standard competent cells 
(described before), which were transformed with linear DNA fragments generated by 
synthetic oligonucleotides hybridization. The fragment contained an HA-tagged gene 
and a kan cassette flanked with FRT sites. Transformants were recovered by shaking at 
permissive for pKD46 temperature and plated on agar with kanamycin for selection. 
Plates were incubated at the non-permissive temperature for pKD46 to eliminate the 
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plasmid. Recombinant bacteria were selected for loss of zeocin and ampicillin 
resistance. 
 
FLP recombination 
 
FLP recombination was used to remove the FRT-flanked kan cassette introduced 
in the revertant mutants (Cherepanov and Wackernagel, 1995). The FLP recombinase, 
which recognizes FRT sites, was expressed from plasmid pCP20. DH10B containing the 
BAC revertants were transformed with an amp resistant plasmid pCP20, recovered and 
incubated at a temperature permissive for replication of the plasmid (30°C). 
Transformants were colony purified at 43°C and selected for loss of kanamycin and 
ampicillin resistance. 
 
 
2.2.1.4. DNA analysis  
 
BAC DNA preparation 
 
BAC Mini preps 
BAC DNA for screening was prepared from 5 ml overnight cultures. Bacteria were 
pelleted and resuspended in S1 buffer, then lyzed in S2 buffer. DNA was cleaned from 
cell debris by incubation with S3 buffer proteins were removed by phenol-chloroform 
extraction. DNA was precipitated with isopropanol, washed in 70% ethanol, and 
resuspended in TE containing RNAse A. 
 
BAC Midi prep 
For further analysis, column purified BAC DNA was prepared using Nucleo Bond PC100 
kit (Midi prep low copy plasmid protocol). The expected yield was 10 μg of BAC DNA. 
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Genomic DNA preparation (buffers Table 11B) 
 
Total DNA was extracted from infected cells. Cells were trypsinized and washed 
in PBS. The pellets were resuspended in PBS and PK buffer, containing Proteinase K 
with 1mg/ml final concentration. Digestion was incubated at 55°C overnight. Proteins 
were removed by a phenol-chloroform extraction. The DNA was precipitated with 1/10 
volume 3M sodium acetate and 2.5 volume absolute ethanol by incubation at -20°C  for 
30 min. Precipitated DNA was pelleted by centrifugation at full speed for 30 min at 4°C. 
The pellet was washed with 70% ethanol, dried, and dissolved in TE buffer containing 
RNAse A (0.1μg/μl). High molecular weight DNA was left overnight at 4°C for 
rehydratation.  
  
Analytical agarose gel electrophoresis 
 
Mutated BACs and derived mutant viruses were characterized by specific 
restriction digestions and separated in 0.6% agarose gel. 
 
 
0.6 %  agarose gel,  0.5x TBE 
 
running buffer:  1.6 L 0.5x TBE 
 (80 ml 10x TBE) 
    5.0 μl Etidium Bromide  
 
gel:   1.8g agarose in 300 ml dH2O  
10 μl Etidium Bromide 
 Run O.N. at 70V 
 
samples:  mix each sample with loading 
  dye, load the gel. 
MINI prep. MIDI prep. 
 
BAC DNA     25.0 μl   5.0  μl 
Enzyme  2.0  μl  1.0  μl 
Buff   3.0  μl  3.0  μl 
dH2O   0           21.0  μl 
 
Total vol. 30 μl 
 
Incubation  2h,  37° C 
 
Digestion  
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Probes for southern and slot blot 
 
Fragments from m142, m143 and M45, cloned in pcDNA, were digested, gel 
purified (Nucleo Spin Extract II kit) and labeled with DIG High Prime DNA labelling kit, 
Roche. Before labelling, the DNA fragments were denaturated at 100°C for 10 min and 
chilled on ice. 
 
Labelling reaction:  
Purified fragment  25 μl 
DIG labelling (vial 1) 5   μl 
Incubate ON at 37oC  
 
After labelling the reaction was inactivated at 65°C for 10 min and purified with Nucleo 
Spin Extract kit II to remove the unincorporated DIG – ddNTPs. 
 
 
Southern blot (buffers Table 11E) 
 
Digested viral DNA was separated in 0.6% agarose gel for 4 hours at 120 V in a 
cool room or ON at 70 V RT. After separation, the gel was denaturated, neutralised and 
equilibrated in appropriate buffers. Gel was blotted as it is described in the Turbo blotter 
manual by Schleicher&Schuell. Blotting was performed at room temperature for 4 hours 
with 20x SSC transfer buffer. The blotting membrane was washed in 2xSSC for 5 min at 
room temperature and fixed at 120 mJ/cm2 in a UV crosslinker (Stratagene). The 
membrane was preincubated with 10 ml hybridization buffer from a DIG High Prime kit 
(Roche) for 30 min at 43°C. Hybridization was done overnight at the same temperature 
with m142 or m143 denaturated probes, following the manufacturer’s instructions. On 
the next day, the membrane was washed 2x 5min with 2xSSC, 0.1% SDS and 2x 15min 
0,5xSSC, 0.1 % SDS at 68°C. Probed DNA was detected as it is described in the DIG 
High Prime kit (Roche) manual. 
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Slot blot 
 
Total DNA extracted from infected cells was loaded on a positively charged nylon 
membrane (ROTI-Nylon Plus) under vacuum with a slot blot device. Samples were 
denaturated in 1 volume 6xSSC buffer at 100°C for 10 min and cooled in an ice/water 
bath. Before loading, slots were washed with 300μl 6xSSC. Samples were loaded under 
vacuum, and slots were again washed with the 6xSSC buffer. The membrane was fixed, 
hybridyzed (probe – M45EX), and detected using the same protocol from DIG High 
Prime kit, Roche. 
 
 
2.2.1.5. RNA analysis 
 
General considerations 
 
In order to prevent RNA from degradation during work, certain rules should be followed: 
 
• Bake the glassware 4 h at 240° C to destroy the RNAses. 
• Treat the water and solutions with DEPC. Subsequent autoclaving is needed to 
inactivate the chemical, because DEPC destroys the RNA. Note that chemicals 
with primary amines, like TRIS cannot be treated with DEPC. 
• Clean the electrophoresis chambers and bench with RNAase-Off reagent 
(AppliChem) and rinse them with DEPC water. 
• Use RNAse free plasticware, plugged tips and single – use pipettes. 
• It is important to keep RNA always on ice and avoid repeated freezing and 
thawing. 
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Preparation of total RNA 
 
Infected cells were lyzed on the plate with TRIzol reagent, containing phenol and 
guanidinium thiocyanate. Phases were separated by centrifugation in phase – lock gel 
tubes (PLG heavy, Eppendorf). The PLG tubes allow better separation of organic and 
inorganic phases and more efficient removal of proteins and high molecular weight DNA. 
RNA was precipitated with isopropanol, washed with 75% ethanol, and dissolved in 
DEPC water. Furthermore, the RNA was column purified (RNeasy kit, Qiagen) and 
DNAse I (Roche) digested to remove any traces of viral and genomic DNA. RNA was 
further washed as described in the manual and eluted from the column in 80 μl DEPC-
treated water. After measuring the RNA concentration, aliquots were stored at – 80°C for 
further analysis. 
 
RNA gel electrophoresis (buffers Table 11C) 
 
RNA quality was tested on a 1.2 % agarose gel, with 0.5 μg of total RNA per sample. 
Samples were mixed with loading dye, denatured for 10 min at 65°C and cool on ice. 
Denaturated samples were loaded on a 1.2% agarose gel, containing 3.7% 
formaldehyde and 1 μl ethidium bromide (10 mg/ml). The gel was run at 50 V. 
 
2.2.1.6. Protein expression and detection (buffers Table 11D) 
 
Expression of different viral and cellular proteins was detected in western blot and 
immunofluorescence. 
 
Cell lyzates preparation 
2.0x105 cells were washed in PBS and lyzed in 100μl lysis buffer, containing protease 
inhibitors (Roche). Cells were incubated on ice for 20 min. After incubation cells were 
collected by scratching and centrifugated to pellet the cell debris. When the cells were 
lyzed in RIPA buffer, columns (Qiashredder, Qiagen) were used to shear the high 
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molecular weight DNA. Cell lyzates were boiled with 1 volume loading buffer at 100°C for 
7 min, cooled on ice and separated by PAGE or stored frozen at -80°C. 
 
Western blot  
Cell lyzates were separated in different percentage PA gels, depending on the size of 
the proteins. 5% PA gels are suitable for separation of large proteins (> 120 kD) as well 
as glycoproteins, 7.5 % for > 25 kD, and 10% for small proteins more than 10 kD. 
 
Table 14. SDS PAAG 
 
After separation, the gel was blotted onto a nitrocellulose membrane (Hybond ECL, 
Amersham Bioscience) in a semi-dry blotting chamber (Biometra). Membrane and 
papers were immersed in water and soaked in transfer buffer. The blotting sandwich 
was assembled as follows, from bottom to the top: 5 sheets of Whatman paper soaked 
in transfer buffer, membrane, gel, cover the free membrane areas with parafilm, put 
another 5 sheets of Whatman papers on top. The blot was run at 1 mA/cm2 for 90 min. 
The blotted membrane was blocked with 5% non-fat milk/PBS or 3% milk/TBS 
(for Cell Signalling antibodies) for 1 h at RT or at 4°C overnight. The membrane was 
incubated with diluted primary antibody (see Table 3). After washing with 0.5% PBS – 
Tween (or TBS-Tween, respectively) buffer, the secondary antibody solution was added 
and incubated at room temperature for 1 hour. The membrane was washed 4 times with 
washing buffer (PBS or TBS-Tween). Signals were detected with detection kit ECL, 
Amersham Bioscience. 
5 % 7.5 % 10 % Staking gel, 4% SDS PAAG 
Mini   large         Mini     large         Mini     large         Mini     large 
AA/BA (37.5:1) 1.7    5.1   ml   2.5       7.5 ml 3.4        10.2 ml 0.7         2.1 ml 
Tricine buffer 3.3    9.9   ml 3.3       9.9 ml 3.3         9.9  ml 1.3         3.9 ml 
Glycerol 86% 1.2    3.6   ml 1.2       3.6  ml 1.2         3.6  ml 0            0 
H2O 3.8    11.4 ml 3.0       9.0  ml 2.1         6.3  ml 3.0         9.0  ml 
Mini gel APS 100μl TEMED 10 μl   
Large gel APS 300μl TEMED 30 μl   
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Immunofluorescence (buffers Table 11G) 
Infected or transduced cells were grown on 1.5 mm cover slips, flamed with ethanol. On 
the day of detection, cells were washed twice with PBS and fixed in 4% 
paraformaldehyde for 20 min at RT. After washing with PBS, cells were incubated with 
ammonium chloride to adjust the pH. The cells were washed with PBS, permeabilized in 
0.3% Triton X-100 / PBS for 10 min at RT and blocked with 0.2% gelatin / PBS for 10 
min at RT. For the counterstaining with propidium iodide, RNAse was added to the 
blocking solution. Cells were incubated with solution containing diluted primary antibody 
for 2 h at 37°C. The unbound antibody was removed by washing 3 times with 1xPBS 
and once with 0.1% Tween 20/PBS. The secondary antibody was diluted as 
recommended (see Table 3) and incubated for 1h at 37°C light-protected. The cover 
slips were washed 4 times with 1xPBS and once with millipore water. The nucleus was 
counterstained with DAPI at 250 μg/ml final concentration or propidium iodide at 1 μg/ml. 
The colour reagent was incubated with the cells for 10 min at RT. Cover slips were 
washed 3 times with millipore water and sealed with Aqua Polymount medium. Samples 
were stored light-protected and analyzed with a confocal microscope. 
 
 
2.2.2. Cell culture and virus propagation  
 
2.2.2.1. Cell lines maintaining  
 
Cell culture propagation 
Mouse NIH-3T3 fibroblasts were cultured in DMEM supplemented with 10% NCS and 
1% Penicillin/Streptomycin (P/S). Cells were split every 3 days at a ratio of 1:5. Stably 
transduced NIH-3T3 (stable cell lines 3T3-m142 HA, 3T3-m143 HA and 3T3 -TRS1 HA) 
were maintained in DMEM containing 5% NCS and 1% P/S. They were split in ration of 
1:5 every 3 days and selected with 0.7% G418 once per month for one week. Phoenix 
cells were grown in DMEM/10% FCS with 1% P/S. They were split 1:5 every 2 – 3 days 
and selected with Hygromycin (300 μg/ml)/Diphteria toxin (1 μg/ml) once monthly for one 
week.  
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Freezing and defreezing of cells 
Cells were stored frozen in liquid nitrogen in freezing medium. For freezing cultured 
subconfluent cells were trypsinized and resuspended in DMEM. Cells were pelleted by 
centrifugation in a precooled rotor at 1200 rpm for 10 min and resuspended in freezing 
medium, which consists of 10% DMSO and 90% FCS.  
Frozen cells were recovered by fast thawing in a 37°C water bath and washing once in 
PBS. Pelleted cells were resuspended in DMEM, supplemented with the appropriate 
serum and antibiotics.  
 
 
2.2.2.2. Stable cell lines 
 
Stable cell lines were created by transduction with retroviral vectors. Phoenix cells 
were seeded 1.5 – 2.0 x 106 in a 6 cm plate and transfected with 5-10 μg DNA retroviral 
vector plasmid containing the gene of interest, using the calcium phosphate precipitation 
method (buffers in Table 11F). The collected supernatant from Phoenix cells (3 ml from 
a plate) was filtered trough a 0.45 μm sterile filter to remove the cell debris. The 
retrovirus containing supernatants were supplied with 5 μg/μl Polybrene (1 μl per 1 ml 
virus) to improve the receptor binding capacity and stored at –80C° or used immediately. 
Target NIH3T3 cells were seeded in a 6cm plate (5x105 NIH3T3) and incubated with the 
supernatant, containing the retrovirus for 4-8 hours. After two days the transduced cells 
were cultivated with medium, containing the G418 to select for positive clones. Selection 
was done for two to three weeks. Cells were tested for expression of the viral proteins, 
expanded and stored frozen in liquid nitrogen. 
 
 
2.2.2.3. Virus propagation  
 
Recombinant and wild-type virus was reconstituted by transfection of the BAC 
DNA into murine embryonic fibroblasts NIH-3T3, or the complementing cell lines using 
transfection reagents Polyfect or Superfect (Qiagen). Protocol was according to the 
  Materials and methods 
 42
producer’s instructions. BAC DNA for transfection was column-purified (NucleoBond 
PC100, Low-copy plasmid protocol, Macherey Nagel) and checked with specific 
digestions. Transfections were performed in 2.5 cm or 6 cm dishes. 
 
 
2.2.2.4. Virus stocks 
 
Subconfluent NIH-3T3 cells were infected with wild-type or revertant viruses. 
Stable cell lines, expressing the corresponding genes were infected with deletion or 
replacement mutant viruses. When all cells showed a cytophathic effect (CPE), the virus 
was harvested. Harvested virus was pelleted at 2000 rpm for 10 min at 4°C to remove 
the cell debris. Virus was centrifuged at 16 000g for up to 4 hours at 4°C and 
resuspended in fresh DMEM, containing 10% NCS. Aliquots were frozen and stored at -
80°C. 
 
 
2.2.2.5. Analysis of virus properties  
 
NIH-3T3 cells were infected at different conditions to study the properties of the 
virus. The multiplicity of infection (MOI) defines the number infectious units per cell. 
 
MOI = virus titer x volume (ml) 
           Cell number 
 
 
Multistep growth curves 
NIH-3T3 cells, wild type or transduced, were infected with a low MOI to show the ability 
of different mutants for spreading. 1.5 x 105 cells per 2.5 cm well were infected with an 
MOI of 0.1. After 2 hours, fresh medium was added (2 ml DMEM/10% NCS). 
Supernatant at the day of infection was collected as a control (day 0). At different time 
points after infection the supernatants of three separate cultures were harvested (2 x 0.5 
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ml) and 1ml fresh media was added until the day 7. Samples were stored frozen at -
80°C.  
 
Single step growth curves 
2.5x105 NIH-3T3 cells were infected at an MOI of 5. After 2 hours the cells were washed 
once with PBS, and 1 ml fresh media was added. Every following day samples from 
three separate cultures were collected (2x250 μl) for 5 days, and 500 μl fresh media was 
added. 
 
RNA transcript analysis 
1.2x106 NIH-3T3 cells were plated in 10cm plates and infected with at an MOI of 1. RNA 
was harvested at 24 and 72 hours after infection. 
 
DNA replication and construct analysis 
2 x 2.5.0x105 NIH-3T3 cells were seeded in 6-well plate, they were infected at an MOI of 
3 with centrifugal enhancement. Virus was calculated for infection at an MOI of 0.3, 
diluted in 2 ml/well DMEM/10% NCS. Cells were centrifuged at 1000g in a centrifuge 
prewarmed to 37°C for 30 min. Twelve hours after infection the medium was changed. 
DNA was harvested 24 and 72 hours post infection. 
 
Viral protein expression 
1.0x 106 NIH-3T3 cells were plated in 6 cm plate and infected with MOI 0.5 to study viral 
protein expression at different times. Proteins were harvested at 24 and 72 hpi. 2.0x105 
NIH-3T3 cells were seeded in 6-well plates and infected at an MOI of 1 to analyze the 
cell host antiviral response. Cell lysates were analyzed in western blot. To study the 
intracellular distribution of viral proteins, 1.0x105 cells per well were seeded on cover 
slips in 12-well plate, infected with MOI 0.5 and fixed at 14 and 24 hpi. Proteins were 
detected by immunofluorescence. 
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Metabolic labeling 
 
Labeling: 
3.0 x 105 NIH-3T3 cells per well were seeded in 6-well plates and infected at an MOI of 
3. Twenty four hours postinfection, the cells were washed with PBS and medium was 
exchanged with RPMI without methionine and cystein (1ml/well), containing 10% FCS 
and 2mM Glutamine (Gibco). Cells were incubated for 1 hour with L – 35S cell labelling 
mix (Amersham), containing 143 μCi total radioactivity per well. Samples were harvested 
as described for western blot, using RIPA buffer. The high molecular DNA was removed 
by centrifugating for 30 min at 13 000 rpm at 4°C. Protein was measured according to 
BCA method and 30 μg of each lyzates were loaded on a 10% PAAG and run overnight.  
 
Detection:  
The gel was fixed for 1 hour in solution containing 250ml ddH2O, 50ml 100% acetic acid 
and 200 ml methanol. The gel was washed 3 times with cold Millipore water and dried 
under a vacuum for 1 hour at 80°C. The dried gel was exposed to X – ray film (Kodak) 
for 1 to 3 hours. 
 
 
2.2.3. Quantification methods 
 
2.2.3.1. Cell number determination 
Cells number was determined by counting in a Neubauer chamber, 0.1mm depth 
and 0.0025 cm2 area. The number of counted cells in 1 big square corresponds to 104 
per 1 ml cell suspension.  
 
2.2.3.2. Spectrophotometric measurements 
Nucleic acid concentration 
DNA and RNA concentrations were determined with a spectrophotometer Nano Drop, 
(PeqLab). The instrument was initialized with 2.0 μl water. Samples (2.0 μl) were 
measured against TE buffer, at optical density A260 and A280. The calculated ratio A260/280 
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indicated unpurity of the sample. A ratio of 1.8 is generally accepted as pure for DNA; a 
ratio of about 2.0 is generally accepted as pure for RNA. Lower ratio in either case may 
indicate the presence of protein, phenol or other contaminants that absorb strongly at 
A280. 
   
Protein concentration 
Equal amounts (2 μl) of the cell lyzates were diluted 1:5 in PBS and incubated with BCA 
protein reagents A+B, mixed in ratio 1:50 (Pierce). The reaction was incubated at 37°C 
for 30 min. In parallel, protein standards were incubated with the BCA reagents for 30 
min at 37°C. After incubation, absorption was measured at λ 492. Protein concentration 
was determined by extrapolation to a standard curve. All samples and standards were 
measured in duplicates. 
 
 Bacteria density 
The density of bacterial cultures was determined with an Eppendorf spectrophotometer. 
One ml sample was measured at λ 600 using LB medium as a reference. 
 
2.2.3.3. Viral titer determination 
 
Median Tissue Culture Infectious Dose method (TCID50) 
Virus titers were determined with the Median Tissue Culture Infectious Dose method 
(TCID50). Cells were seeded 4x105 in a 96 well plate with 100μl DMEM per well. They 
were infected with 100μl per well increasing 10-fold virus dilutions (Table 15). Titers 
were read after 7 days. 
Cells infected with MCMV-GFP-based viruses show green fluorescence, which allows a 
faster detection and easier titer determination. The following formula was used to 
calculate the virus titer:  
 
Titer (TCID50) = wells with CPE in one row x highest dilution with CPE 
            0.1 ml virus suspension 
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Table 15. Ten – fold dilutions for TCID50/mL 
 
 
 
Statistical significance  
For the virus growth analysis and stocks, each titration was done in triplicate. For the 
growth curves, the average and the standard deviation were calculated. 
Row in the plate 
(x 100 μl / well) 
Dilution fold DMEM / ml 
 
Virus 
A 10-1 1 350 150 μl undiluted 
B 10-2 1 350 150 μl virus 10-1 
C 10-3 1 350 150 μl virus 10-2 
D 10-4 1 350 150 μl virus 10-3 
E 10-5 1 350 150 μl virus 10-4 
F 10-6 1 350 150 μl virus 10-5 
G 10-7 1 350 150 μl virus 10-6 
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3. RESULTS 
 
 
Previous studies have provided indirect evidence for essential role of m142 and 
m143. To perform a functional analysis and investigate the role of m142 and m143 for 
MCMV replication, the genes were deleted and mutant viruses were analyzed for their 
growth properties and viral gene expression. Additionally, the MCMV genes were 
compared to the US22 gene family members of HCMV, TRS1 and IRS1, to find possible 
functional homologies. 
 
3.1. Construction and propagation of mutant viruses  
 
For construction of mutant viruses, the MCMV genome cloned as infectious 
bacterial artificial chromosome (BAC), was modified by targeted mutagenesis. Deletions 
and insertions into the viral genome were performed by homologous recombination of 
MCMV-GFP, cloned as a BAC, and a fragment containing the corresponding gene and 
sequence homologous to the target sequence. The fragments for homologous 
recombination were made by cloning of m142, m143 and TRS1 in different vectors. 
 
 
3.1.1. Cloning and expression of m142 and m143 
 
The genes m142 and m143 were amplified from the MCMV genome and cloned 
in expression vectors to verify the sequences. The HCMV genes TRS1 and IRS1 were 
amplified from the HCMV AD169 laboratory strain, cloned in expression vectors and 
sequenced. The m142, m143 and TRS1/IRS1 were amplified (Fig. 7) as epitope tagged 
genes with primers that include a hemaglutinin (HA) tag sequence at the 3’ end of the 
coding sequence as described in Materials and methods, table 8.  
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The amplified fragments were cloned into expression vector pcDNA3 to generate 
the plasmids pcDNA-m142HA, pcDNA-m143HA, pcDNA-TRS1HA and pcDNA-IRS1HA 
(see Appendix 1 A). The constructs were digested with specific enzymes to confirm the 
right inserts (Fig.8).  
Cloned genes were sequenced with standard T7 and SP6 primers, and the data 
was compared with published sequences at Genbank. BLAST was performed using 
reference sequences with accession numbers U68299 for the MCMV Smith strain and 
X17403 for the HCMV AD169 laboratory strain. Data analysis showed several single 
nucleotide mismatches found in ORFs m143, TRS1 and IRS1 regarding published 
MCMV and HCMV sequences, the changes are shown in appendix 2.  
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Fig.7 Amplification of m142, m143 and TRS1 as HA tagged genes. 
pcDNA m143 pcDNA m142 pcDNA TRS1 
 1.6kb  1.3 kb  2.5 kb 
BamHI/EcoRI EcoRI/XhoI  EcoRI/XhoI  
7.3 kb 7.2kb 
6.8 kb 1.5 kb 
NotI 
0.4kb 
0.3kb 
0.8 kb 
BamHI  XhoI 
Fig. 8 Cloning in pcDNA 3. Cloned genes were confirmed with specific digestions.
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3.1.2. BAC mutagenesis 
 
The homologous recombination was performed in E.coli strain DY380, which 
contains a prophague, expressing recombinases under control of a temperature senstive 
promoter (see Table 4). 
Deletion mutants (Δ142, Δ143) were created by replacing ORFs m142 and m143 
with a zeocin resistance gene. The zeocin cassette was amplified from pZEO4, flanked 
with sequences homologous to adjacent regions of m142, m143 or m142/m143. The 
purified fragment was transformed into E.coli DY380 electrocompetent bacteria 
containing the MCMV-GFP BAC genome (Fig 9A, Table 17). Both genes are encoded 
on the complementary strand. They were deleted, respectively, for m142 ORF from 200 
798 to 199 671 nt and for ORF m143 from 202 563 to 201 121 nt. A double knockout 
mutant (Δ142/143) was created, spanning deletion from 202 563 to 199 621 nt.  
In order to demonstrate that the phenotypes of the deletion mutants were due to 
the lacking genes, m142 and m143 were reinserted into the MCMV genome. The 
revertant mutants (r142, r143) were based on deletion mutant BACs, where m142 or 
m143 were re-introduced as HA-tagged genes. Fragments for recombination were 
derived from helper vectors pBSo142/m142 HA kan and pBSo143/m143 HA kan. The 
helper vectors were created by cloning of hybridized synthetic oligonucleotides, 
including restriction sites and 50bp homologous regions flanking ORFs m142 or m143. 
The sequences of synthesized oligonucleotides are presented in Table 8. 
 
 
 
 
 
 
 
 
 
 
 
Fg.9 Targeted mutagenesis. A. The black arrow indicates zeocine cassete; B. 
Corresponding HA tagged genes are shown with hatched box. C HA tagged genes 
were inserted at the place of m02 – 06 ORFs with kan FRT cassette and PGK 
promoter.  
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Resulting plasmids (pBS o142 and pBS o143, Fig. 10) served as vectors for 
cloning the HA tagged genes m142 and m143 derived from pcDNA constructs.  
 
A B
 
 
 
 
 
 
 
Fig. 10 Helper vectors for recombination, containing oligonucleotides homologous to 
m142 (A) or m143 (B) and carrying specific restriction sites. 
Additionally, to select the mutants conatining re-inserted genes, a kanamycin 
cassette flanked by FRT sites (kanFRT) was cloned into the described plasmid (see 
App1 and Table 16).  
 
pBSm0206PGK-E3L pBSm0206PGK-kan pCI E3L 
pBSm0206PGK-IRS1HA pBSm0206PGK-kan pcDNAIRS1HA 
pBSm0206PGK-TRS1HA pBSm0206PGK-kan pcDNATRS1HA 
pBSo143-E3L pBSo143 pCI E3L 
pBSo142-E3L pBSo142 pCI E3L 
pBSo143-TRS1HA pBSo143 pcDNATRS1HA 
pBSo142-TRS1HA pBSo142 pcDNATRS1HA 
pBSo143-m143HA pBSo143 pcDNA m143HA 
pBSo142-m142HA pBSo142 pcDNA m142HA 
Resulted plasmid Vector molecule: Insert cut from:  
 
 
 
 
 
 
 
 
 
pBSo143-E3L/kan EcoRI pBSo143-E3L 
pBSo142-E3L/kan EcoRI, blunted pBSo142-E3L 
pBSo143-m143HA/kan EcoRI pBSo143-m143HA EcoRI 
pBSo142-m142HA/kan EcoRI, blunted pBSo142-m142HA HpaI 
Resulted helper plasmid Cut pSLFRTkan: Cut helper plasmid:  
 
 
 
 
 Table. 16.  Description of constructed helper vectors. 
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The fragments including oligonucleotides, HA-tagged genes and kanFRT 
cassette, were excised from the helper plasmid and transformed into electrocompetent 
DY380 cells, which carried Δ142 MCMV-GFP BAC or Δ143 MCMV-GFP BAC genome 
(Fig 9B, Table17). 
 
 
 
 
 
 
 
 
 
 
 
 
 Cam + kanNone Δ m143Kan-TRS1HA-o143Replacement TRS1/o143
Cam + kanNone Δ m142Kan-TRS1HA-o142Replacement TRS1/o142
Kan + Cam + 
Zeo
+ Δ m143 PGK m0206 TRS1 HA 
 
Replacement PGK – TRS1 
delta m143 
Kan + Cam + 
Zeo
+ Δ m142 PGK m0206 TRS1 HA Replacement PGK – TRS1 
delta m142 
CamNone FRT sitesKan cassette (to cut )Revertant m143 HA K-
CamNone FRT sitesKan cassette (to cut )Revertant m142 HA K-
Cam + Kan+ Δ m143m143 HA-o143Revertant m143 HA 
Cam + Kan+ Δ m142m142 HA-o142Revertant m142 HA 
Cam + ZeoNone Wild typeZeo-m142/m143Δ m142/m143 
Cam + ZeoNone Wild typeZeo-m143Δ m143 
Cam + ZeoNone Wild typeZeo-m142Δ m142 
Resulting 
resistance
Kan 
cassette 
Target sequence
BAC MCMV-GFP
Fragment for 
recombination
Mutant BAC 
Table. 17.  Description of the recombinant BAC genomes.  
 
The recombination resulted in replacing the target sequence containing zeocin in 
the deletion mutants with a fragment flanked by homologous arms, including the 
corresponding gene, and a kanamycin cassette for selection. Mutants were selected for 
kanamycin resistance and loss of zeocin resistance. Because the insertion mutants were 
made to have a phenotype comparable to the wild type MCMV, the kan cassette was 
subsequently removed by FLP recombination, leaving behind one short FRT sites. 
 
 
3.1.3. Construct characterization 
 
Targeted mutagenesis of the MCMV genome resulted in insertions of 
heterologous genes, or at least restriction site changes which determined specific 
digestion patterns. Recombinant BAC genomes were characterized by EcoRI digestions. 
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Digested BACs were separated in 0.6% agarose gel and stained with ethidium bromide 
(Fig. 11).  
Homologous recombination of the wild-type MCMV-GFP genome with the zeocin 
cassette resulted in an additional EcoRI site and disruption of the 9 kb fragment 
containing the ORFs m142 and m143. The Δm142 has additional bands at 1.8 and 6.6 
kb, whereas Δm143 is characterized by the appearance of new fragment at 3.4 kb (Fig 
11 A and B).  
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Fig.11 Charcterisation of recombinant BAC genomes by EcoRI digestion. A. Schematic 
drawing of the BAC mutants, the open arrows depict an ORF and the small ones indicate 
EcoRI restriction sites. Large black arrow represent the zeocine cassette. B. Ethidium 
bromide stained gel of digested BAC mutants: wild type (lane1), Δ m142 (lane2), Δ m143 
(lane3), revertant m142 (lane4), revertant m143 (lane5), TRS1 Δm142 (lane6) and TRS1 
Δm143 (lane7). C. Characterisation of the double deletion mutant (ΔM) with EcoRI 
digestion. The construct is shown at lower the part in panel A. 
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The replacement of both ORFs m142 and m143 with zeocin cassette, resulted in 
appearance of a 1.8 kb band and disruption of the 9 kb fragment (Fig. 11 A and C). 
Reinsertion of the HA-tagged genes m142 and m143, resulted in three new EcoRI 
fragments. The revertant m142 is distinguished by the presence of a 6.6 kb band and 
revertant m143, has additional bands at 2.7 and 6.4 kb.the reinsertion of HA-tagged 
m142 or m143 resulted in disruption of the 9 kb EcoRI fragment which contains the 
entire m142 and m143 ORFs in the MCMV genome (Fig. 11 A and B).  
 
 
3.1.4. Virus propagation 
 
Mutant BAC genomes were transfected into NIH3T3 cells. The wild type and 
revertant BAC genomes produced infectious virus, whereas the deletion mutants did not 
grow. To overcome this problem, the viral genes m142 and m143 were expressed from 
NIH3T3 cells. To create stable cell lines, expressing m142 or m143, the corresponding 
genes were subcloned into retroviral vectors. The HA-tagged genes m142 and m143, 
were excised from pcDNA constructs and subcloned into plasmids containing the 
retroviral backbones pLXSN or pLXRN to obtain the constructs pLXSN m142HA, pLXRN 
m143HA and pLXSN TRS1HA (see Appendix 1B). The genes m142 and TRS1 were cut 
from pcDNAm142HA or pcDNATRS1HA with EcoRI/XhoI and cloned into pLXSN at 
EcoRI/XhoI; m143 was cut from pcDNAm143HA with BamHI/EcoRV and cloned into 
pLXRN into BamHI/HpaI. Vector constructs were verified with specific digestions (Fig 
12). 
pLXSN-m142 HA pLXRN-m143 HA
1.3 kb
C
3-4
C
3-3
C
3-2
C
2-4
EcoRI/XhoI
1.6 kb
C
3-4
C
3-1
BamHI/EcoRI
pLXSN-TRS1 HA
C
6
C
5
C
4
C
3
C
2
XhoI/EcoRI
2.5 kb
 
 
Fig. 12  Retroviral vector characterisation. Constructs were checked with specific 
digestions. Different clones (C2....C6) were anlysed. 
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The retroviral vectors contain elements derived from the Moloney murine 
leukaemia virus (MoMuLV) and Moloney murine sarcoma virus. They encode the 
extended viral packaging signal (psi) and a Geneticin (G418) resistence gene, which is 
used for selection in eukaryotic cells. The expression of inserted genes is controlled by 
the retroviral promoter, located at the 5’ long terminal repeat (5’ LTR), whereas the G418 
is expressed from an independent simian virus 40 (in pLXSN) or a Rous sarcoma virus 
(in pLXRN) promoter. To produce an infectious, replication-competent virus, the vector 
was transfected into a packaging cell line, which provides the structural viral genes (gag, 
pol and env) necessary for particle formation and replication. Thus, the retroviral 
constructs, containing the corresponding gene and a G418 resistance gene were 
transfected into Phoenix packaging cells (Table 5) (Fig 13 A). The packaged virus is 
released from the cells into the supernatant. Harvested recombinant retrovirus was used 
to transduce target NIH3T3 cells. MoMuLV is a retrovirus, which can stably integrate into 
the cellular genome and thereby deliver the inserted heterologous gene.  
 
 
 
 
 
 
 
 
 
 
 
 
Transduce mouse fibroblasts 
Recombinant retrovirus 
gene 
LTR
HA G418 
LTR
LTRLTR
Retroviral vector 
G418 
m142 HA
m143 HA
 
 
A 
Stable cell lines NIH3T3 
Selection with G418 
Packaging cell line 
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The transduced cells were cultivated with G418 to select for positive clones. 
Successful integration and expression of the inserted genes was controlled in 
immunofluorescence assay and expected size of the proteins was confirmed in western 
blot. Further the expression was maintained by temporary cultivation of the transduced 
cells with G418 to ensure a long term optimal expression of m142 and m143 (Fig. 13 B 
and C). Additionally, a cell line expressing TRS1 was created to test deletion mutants for 
complementation (Fig. 13 B and C). 
 
 
3.1.5. Virus complementation 
 
The NIH3T3 cells expressing m142 or m143 were transfected with the deletion 
mutant BAC genomes. Virus was successfully regrown, indicating that the expression of 
viral genes, m142 and m143 from NIH3T3 cells can complement the deletion mutants 
(Fig 14).  
-m142 
-m143 
-TRS1 
Fig.13. Stable cell lines, protein expression. A. Original NIH3T3 cells were transduced 
with recombinant retrovirus, containing m142, m143 or TRS1 HA tagged genes and 
G418 resistance gene. Protein expression was verified in B. Immunofluorescence (IF) 
and C. western blot of stable cell lines. Anti – HA tag antibodies were used to detect 
the proteins: 3F10 for IF and 16B12 for western blot. 
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Fig. 14. Deletion mutants were regrown on complementing cells. A. Δ m142 grows 
on NIH3T3 - m142 and B. Δ m143 grows on NIH3T3 - m143. 
 
 
 
In several attempts it was not possible to regrow the double deletion mutant on 
original or complementing cells. This fact supports the hypothesis that m142 and m143 
are required together for the virus to complete successful replication. 
 
3.1.6. Virus growth on original NIH3T3 cells 
 
 The reconstituted viruses were used to infect non-complementing NIH3T3 cells.  
The deletion mutants failed to produce a virus at detectable levels (Fig 15 A). However, 
the revertant viruses containing reinserted m142 or m143 grew to similar titers as the 
wild-type MCMV (Fig. 15 C), indicating that the defect of the deletion mutants is due to 
the lacking genes. Obviously, the insertion of the missing genes restored the wild type-
like phenotype, showing that both, m142 and m143, are required for the virus to grow. In 
some cases the effect of a missing viral gene can be compensated by high MOI 
infection. For instance, deletion of the HCMV gene IE1 results in replication-deficient 
virus, but infection at a high MOI can rescue the replication (Greaves and Mocarski, 
1998; Mocarski et al., 1996). The deletion mutants Δm142 and Δm143 did not grow on 
non complementing NIH3T3 cells even at high MOI infection (Fig.15 B).  
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Fig. 15. Deletion mutants cannot grow on original NIH3T3 cells at low (A) or high (B) 
MOI infection. Reinsertion of m142 and m143 into the MCMV genome restores the 
wild type phenotype (C). 
This result clearly shows that m142 and m143 are essential for virus replication 
and corresponds to the published data, that disruption of m142 and m143 results in 
impaired virus growth (Menard et al., 2003). The presence of one of these genes is not 
sufficient to restore the wild type-like phenotype, only when both m142 and m143 are 
present the virus can grow. This fact, together with the observation that double deletion 
mutant BAC (Δm142/m143) could not be reconstituted, suggests that m142 and m143 
are required together in the context of viral infection.  
 
  
 
3.1.7. Mutant virus genome  
 
The confirmation of the essential role of m142 and m143 for virus replication was 
an important starting point for the followed experiments. Therefore, the virus 
preparations were verified to confirm the constructs and exclude contamination with the 
wild type MCMV-GFP. Viruses derived from mutant BAC genomes were grown on 
original or complementing cells. Total DNA from infected cells was digested with EcoRI 
and separated in agarose gel. The DNA was blotted onto a nylon membrane and probed 
for m142 and m143 (Fig. 17). To verify the deletions and insertions that resulted from 
the targeted mutagenesis, expected bands were calculated on the basis of mutated BAC 
 57
  Results  
 58
genomes. The detected bands corresponded to the band size from the EcoRI digestion 
of the BAC mutants. All mutant viruses lack the 9 kb fragment as a result from disruption 
due to the insertions, excluding possible contamination with the wild type MCMV-GFP. 
Probes were made from DIG labeled fragments, derived from pcDNA constructs 
containing m142 or m143. Fragments were purified and labeled as described in 
Materials and methods. 
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Fig.16 The MCMV BAC based viruses were confirmed by Southern blot. A. 
Recombinant BAC genomes were transfected into NIH3T3 cells. B. Virus genomes
were confirmed with probes for m142 and m143. 
 
 
 
 
 
The mutants containing reinserted HA-tagged genes, m142 or m143, were further 
characterized to demonstrated their functional capability. The expression of the inserted 
gene is controlled by the corresponding promoters, of m142 or m143, respectively, and 
 
 
expected to be expressed at immediate-early times. Non-complementing NIH3T3 cells 
were infected with revertant mutants and fixed after 24 hours postinfection. 
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Fig. 17 Expression of HA tagged 
revertant viruses. The HA-tagged proteins were detected with a specific ant-HA 
antibody 16B12 in western blot (A) or 3F10 in immunofluorescence (B). 
m142 and m143 in NIH3T3 cells infected with 
 
The expression of m142 and m143 was detected with an anti-HA tag antibody
(Fig.17 B). Laser scanning image analysis showed a predominan
 
tly cytoplasmic 
localization of the MCMV proteins m142 and m143. The protein size was confirmed in 
wester
 recently reported 
data b
 mutants 
 
The core aim of the present work was to study the function of m142 and m143. To 
tion, deletion mutants were used to 
infect non-complementing cells and study viral gene expression in the context of viral 
infection.  
n blot of infected cells with an anti-HA tag antibody (Fig17 A).  
These results confirmed that the reinserted m142 and m143 are expressed and 
appropriately localized in the context of viral infection. The size and intracellular 
distribution of the studied proteins was in complete agreement with
y Hanson and co workers (2005). 
 
 
 
3.2. Functional analysis of the deletion
analyse the role of m142 and m143 for virus replica
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3.2.1. Viral gene expression and replication 
 
CMV replication is a synchronized process governed by viral and host factors, which 
results in accumulation of viral DNA. Analysis of DNA extracted from infected cells 
showed that deletion mutants synthesize reduced amounts of DNA at 72 hours 
postinfection (Fig 18). NIH3T3 cells were infected with mutant viruses and DNA was 
extracted at 24 and 72 hours postinfection. Total DNA was blotted and probed with DIG 
labelled M45 fragment. The probe was generated from a pcDNA-M45 construct, cut with 
EcoRI and XhoI restriction enzymes. The 1.9 kb fragment was purified and labelled as 
described in Materials and methods. Thus, deletion mutants failed to accumulate viral 
DNA, indicating that m142 and m143 are both required for successful replication.  
Fig. 18 Viral DNA replication  
 
This result suggested that the replication defect could be a consequence of a block in 
the gene cascade expression. To investigate this, the expression of viral genes re-
presenting different kinetic classes was analysed. Expression of viral proteins was 
detected at 24 hours postinfection. In addition, samples were harvested also at 72 hours 
postinfection to show a possible delay of expression by the mutant viruses. The 
experiment demonstrated that expression of viral proteins with immediate-early, early, or 
early-late kinetic was not changed dramatically. The corresponding proteins, IE1, E1 and 
M44, were detected at 24 and 72 hours postinfection in all mutants, although the IE1 
was less expressed by the deletion mutants (Fig. 19). In contrast, the late protein gB 
was not detected at 72 hours postinfection, indicating that m142 and m143 are required 
for late gene expression. Since earlier studies have reported a transcriptional 
transactivating function for the US22 gene family members TRS1 and IRS1 (Stasiak and 
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Mokarski; Romanowski and Shenk, 1997), it was considered that m142 and m143 might 
have a transactivating function.  
 
Fig. 19 Viral genes expression at 24 (A) and 72 hpi (B).  
 
Although a more recent report (Hanson et al., 2005) showed that m142 and m143 
failed to transactivate genes in transient transfection assays, it was tested whether these 
genes are required for the late gene transcription in the context of viral infection. Late 
gene transcripts, coding for the early-late gene M44 and late genes M55(gB) and 
M100(gM) were evaluated by real-time PCR (data provided by Marcus Picard-Maureau).  
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Fig 20. RNA transcript analysis. A. Early  late proteins M44. B Late proteins gB and 
gM. Data kindly provided by Marcus Picard-Maureau. 
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Analysis of RNA transcripts did not show a significant decrease in RNA levels for gB 
at 24 and 72 hpi. The only observed difference was for Δm143, where RNA was 10-fold 
decreased. The same result was shown for the other transcripts. RNA was analyzed 
also for the early late gene product M44 and that corresponds to the protein expression 
pattern, where no difference to the wild-type virus was observed (Fig. 20).  
The analyzed data showed that m142 and m143 are not involved in regulation of the 
late gene transcription. However, the late protein gB was not detected, suggesting that 
protein synthesis is inhibited at the posttranslational level. This observation was 
confirmed by an experiment, which demonstrated a global protein synthesis shut down 
in cells, infected with deletion mutants. The cells were infected with mutant viruses and 
protein synthesis was analyzed by metabolic labeling with (35S)-methionine and -
cysteine. The proteins were separated by SDS-PAGE and visualized by exposing to an 
X-ray film (Fig 21).  
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Fig. 21. Protein synthesis shut down. Metabolic labeling of infected cells.  
 
It was clearly visible that deletion mutant-infected cells showed reduced protein 
synthesis, suggesting that m142 and m143 are required to prevent the global shut down 
of protein synthesis. 
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3.2.2. Protein synthesis inhibition   
 
The global protein synthesis shut down is one of the mechanisms that results from 
the activated antiviral response and leads to limiting the viral infection. It represents the 
earliest defense of the infected cell, which involves IFNα/β induction (Fig 22). The 
pathway is triggered by dsRNA, resulting from the virus replication. MCMV is a double 
stranded DNA virus which carries RNA molecules. Moreover viral gene transcription 
may result in dsRNA structures, formed by opposing transcripts. Viral dsRNA is a strong 
inducer of IFNα/β genes and therefore plays an important role in antiviral defense during 
innate immune response. Double-stranded RNA triggers the expression of IFN-
stimulated genes or upregulates and activates effector proteins with antiviral activity. 
Some viral genes encode proteins that counteract the effector antiviral proteins and 
prevent consequent translation arrest.  Since the RNA analses showed that late 
transcripts were present but protein synthesis was impaired in cells infected with the 
deletion mutants, it was suggested that the products of m142 and m143 are involved in 
preventing the protein synthesis shut down during the antiviral response. 
 
 
 
 
 
 
 
 
 
 
 
 Fig.22. Antiviral response and immune evasion mechanisms. 
 
To test this hypothesis, the pathway leading to translational arrest upon IFN induction 
was investigated. This signalling involves the cellular protein dsRNA-dependent 
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proteinase K (PKR), which phosphorylates the α subunit of the translational factor eIF2. 
The phosphorylated eIF2α is inactive and the protein synthesis is blocked. Western blot 
analysis of infected cells showed that the PKR and eIF2α are phosphorylated when 
m142 or m143 were deleted (Fig 23). Western blot analysis of infected cells showed that 
infection with deletion mutants resuts in a mobility shift of the bands detected with an 
anti-PKR antibody. Moreover the initiation factor of translation, eIF2α was 
phosphorylated in cells infected with the deletion mutants (fig 23 A). The appearance of 
additional bands for PKR was associated with activation, e.g. phosphoralytion since cells 
infected with deletion mutants showed reduced protein synthesis (Fig 21). This 
assumption was confirmed by detection of the phosphorylated form of PKR by an anti-
phopsho PKR antibody (pT451), shown in figure 23B. Another experiment demonstrated 
that treatment of NIH3T3 cells with the dsRNA homolog poly I:poly C results in a similar 
mobility shift of the PKR bands (Fig 23B). 
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Fig. 23 Phosphorylation of PKR and eIF2α. A. Infection with deletion mutants results in 
phosphorylation of eIF2α and mobility shift of PR. B. PKR is phosphorylated when m142 
or m143 are deleted. C. Detection of phoshop-PKR in cells infected with deletion mutants, 
compared to the wild type and revertant viruses. 
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PKR is normally inactive, but is activated by binding to dsRNA. The activation 
leads to conformational changes and unmasking of a catalytic domain. The active form 
is a dimer, with two PKR molecules binding one dsRNA molecule. The two PKR 
molecules phosphorylate one an other at several serines and threonines. Activated PKR 
phosphorylates the α subunit of the eukaryotic translation initiation factor eIF2 (eIF2α) 
and prevents recycling of initiation factors (Clemens and Elia, 1997). The eIF2 consists 
of three subunits (α, β and γ), and is responsible for recruitment of the small ribosomal 
unit. GTP-bound eIF2 forms a complex with the initiator Met-tRNA in the initial step of 
translation. The complex interacts with mRNA, the large ribosomal subunit and 
additional initiation factors to form a pre-initiation complex. Subsequently the GTP bound 
to the eIF2 is hydrolyzed. The GDP-eIF2 (hydrolyzed form) must be exchanged for GTP 
to be able to participate in next round of translation initiation. The exchange reaction is 
catalyzed by the guanine exchange factor eIF2B. The binding of phopshorylated eIF2α 
with eIF2B, is irreversible and the recycling of eIF2 is blocked (Clemens and Elia, 1997). 
Since the cellular levels of eIF2B are limited, the translation is inhibited.  
The described experiments showed that deletion of m142 and m143 results in 
phopshorylation of the eIF2α and activation of PKR, reinforcing the conclusion that 
protein synthesis of infected cells with deletion mutants is inhibited as a result of PKR-
mediated translational arrest. This suggests that m142 and m143 encode proteins that 
are necessary to prevent PKR and eIF2α phosphorylation. 
 
3.2.3. Functional homologues of m142 and m143 
 
The MCMV genes m142 and m143 are the closest sequence homologues of the 
HCMV genes TRS1 and IRS1. This fact was supported by the published data that TRS1 
can rescue the replication of the vaccinia virus mutant lacking the E3L gene (Child et al., 
2004) and a herpes simplex virus mutant lacking the γ134.5 gene (Cassady, 2005). The 
products of E3L and γ134.5 have been reported to have role in preventing the PKR 
mediated protein synthesis shut down. Since the present work showed that m142 and 
m143 deletion results in PKR mediated protein synthesis inhibition, a possible functional 
homology of m142 and m143 with the HCMV genes TRS1 and IRS1 was considered. 
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 To test whether TRS1 can substitute for either m143 or m142, several 
replacement mutants were created. The heterologous gene was inserted at different 
positions, under control of different promoters (Fig.24).  
 
 
 
  
 
 
TRS1 was cloned into the pBS o142 and pBS o143 plasmids, which contain 
homologous sequences to m142 or m143 (see Appendix 1C). The resulting helper 
vectors are described in table 17. The fragment containing TRS1, flanked by m142 or 
m143 homologous sequences was inserted at the deletion BAC genome. The 
recombination resulted in replacing the zeocine cassette with an HA-tagged TRS1, 
where the expression was controlled by m142 or m143 promoters. The mutated 
genomes were reconstituted on complementing cells. The derived viruses, were used to 
infect non-complementing NIH3T3 cells. However, neither of the mutants yielded a 
replication-competent virus. Since it has been already shown by Hanson and co-workers 
(2005) that m142 and m143 have relatively weak promoters it was not an unexpected 
result. Further, it was considered preparing a construct where TRS1 expression is driven 
by another promoter. For this, a helper plasmid was used, which contains 50bp 
sequences homologous to the region upstream of m02 and downstream of m06 ORFs, a 
kanFRT cassette, and a phosphoglycerate kinase (PGK) promoter (Jurak and Brune, 
2006). The HA-tagged TRS1 was cloned into the described plasmid and derived a 
fragment, including PGK promoter, HA tagged TRS1 and m02 – m06 homologous arms 
and kan cassette (Fig 8C). The fragment was excised from the vector and transformed 
into bacteria carrying Δ142 MCMV GFP BAC or Δ143 MCMV GFP BAC genome. 
Fig. 24. TRS1 replacement mutants. PGK-phosphoglycerate kinase promoter, 
KAN-kanamycin cassette, black arrow shows the zeocin resistance gene. 
TRS1-Δ m142 
TRS1-Δ m143 m02 KAN TRS1 PGK m06 m141 m142 m144 
m141 m143 m144 m02 KAN TRS1 PGK m06 
TRS1/ m142 
TRS1/ m143 
m142 m141 m144 TRS1 
m02 m03 m04 m05 m06 m143 m141 m144 TRS1 
m02 m03 m04 m05 m06 
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Recombination resulted in insertion of TRS1 into the MCMV deletion mutant genomes. 
Construction of the recombinant BAC is presented in table 17. 
 Recombinant BAC genomes were characterized by EcoRI digestion. The 
insertion of fragment including the PGK promoter, HA-tagged TRS1 and a kanFRT 
cassette, resulted in disruption of the 22 kb EcoRI band. Additionally, the insertion 
mutants have the bands showing the replacement of m142 or m143 ORFs by a zeocin 
gene (Fig. 10). The verified mutant BAC genomes were transfected into complementing 
cells and NIH3T3 cells were infected with the derived virus. The correct insertion of 
TRS1 into the viral genome was confirmed by southern blot (Fig. 15). Total viral DNA 
extracted from infected cells was digested with EcoRI and probed for m142 or m143. 
Southern blot showed that the 9.0 kb EcoRI fragment, containing the entire m142 and 
m143 ORFs is not present, excluding possible contamination with wild type MCMV. 
Deletion of m142 and m143 was verified by the absence of the corresponding bands. 
The HCMV gene TRS1 was introduced into the MCMV genome as an HA-tagged gene. 
Expression of TRS1 in the context of viral infection was shown in western blot. The 
confocal microscope analysis of NIH3T3 cells infected with MCMV-TRS1 mutants, 
showed that the protein, encoded by the inserted gene is distributed in the cell 
predominantly in the cytoplasm (Fig. 25). This corresponds with previously published 
data on TRS1 in HCMV infected cells (Romanowski and Shenk, 1997).The mutants 
TRS1-Δm142 and TRS1-Δm143 could grow on non-complementing NIH3T3 cells (Fig 26 
A). Although the titers were about 100-fold lower than the wild type, these data 
suggested that TRS1 can substitute for m142 and m143. This finding was confirmed by 
complementation of deletion mutant viruses. NIH3T3 cells were transduced with a 
recombinant retrovirus, containing HA-tagged TRS1. 
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Fig. 25. Characterisation of the TRS1 mutants.  The HA tagged TRS1 is expressed in 
NIH3T3 cells infected with TRS1 mutants. A. Wetsren blot B. Immunofluorescence. 
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Cells were selected and characterized. The size of the protein was confirmed in 
western blot. Confocal image analysis showed the expected intracellular distribution. 
Infection of the complementing cells demonstrated that TRS1 can complement for m142 
and m143, when provided in trans-position (Fig 26 B). This observation supports the 
idea that TRS1 is a functional homologue of m142 and m143. Moreover, the insertion of 
TRS1 into a deletion mutant genome restores the expression of late proteins (Fig 27). 
Although IE1 and gB have reduced levels compared to the wild-type virus, which is 
relevant to the lower titers that replacement mutants can reach. This suggested partial 
functional homology of TRS1 with the MCMV genes m142 and m143.  
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Fig. 26 TRS1 can substitute for m142 and m143. A. Insertion mutants grow on NIH3T3 
cells. B. Deletion mutants grow on TRS1 expressing NIH3T3 cells. 
 TΔ m
143 
TΔ m
142 
M
ock 
W
T A B 
TΔ m
143 
TΔ m
142 
M
ock 
W
T  
 
 
IE1 
 
E1 
M44  
 gB 
 β-actin 
 
 
 
 
Fig. 27 The late protein expression is restored by insertion of TRS1. Infected NIH3T3 
cells were harvested at 24 (A) and 72 hpi (B). 
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The successful complementation of m142 and m143 with TRS1 suggested that 
other genes closely related to TRS1 could also substitute for m142 and m143. The most 
appreciated candidates were the sequence homolog IRS1 and the vaccina virus E3L 
gene, which was recently shown to be complemented by TRS1 (Child et al, 2004). 
Several different mutants were created as described above (Fig.28). Mutated BAC 
genomes were reconstituted on complementing cells and the derived vrius was used to 
infect NIH3T3 cells.  
 
 
 
 
 
However, insertion of IRS1 under control of PGK promoter did not complement 
the m142 and m143. This suggested that IRS1 is more distant from m142 and m143 
than TRS1 in functional respect. The attempt to substitute m142 and m143 with the 
vaccinia virus gene E3L was unsuccessful even when the gene was expressed from the 
PGK promoter. In this case, a possible explanation might be the fact that poxviruses are 
more distant biological species. 
 
3.3. Conclusion 
 
The presented data showed that the MCMV genes m142 and m143 are essential 
for the virus replication. They are not involved in viral gene transcription, but required for 
late protein expression. The m142 and m143 proteins were found to prevent PKR and 
eIF2α phosphorylation during infection, thereby avoiding the protein synthesis shut-
down as part of the antiviral response. Comparison of the MCMV genes m142 and m143 
m02 KAN IRS1 PGK m06 
m141 m143 m144 
m141 m142 m144 
m02 KAN E3L PGK m06 
m02 KAN E3L PGK m06 
m02 IRS1-Δ m142 KAN PGK IRS1 m06 
IRS1-Δ m143 
m141 m143 m144 
m141 m142 m144 E3L-Δ m143 
E3L-Δ m142 
Fig. 28. Other insertion mutants. The HCMV gene IRS1 and vaccinia virus E3L were 
inserted at the m02-m06 position under control of a PGK promoter.IRS1-Δ m142 
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with the closely related HCMV gene TRS1 showed partial functional homology. These 
results demonstrated that m142 and m143 are essential for the MCMV replication 
because they encode proteins that counteract the host antiviral response.  
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4. DISCUSSION  
 
 
4.1. The MCMV genes m142 and m143 are essential US22 gene family 
members 
 
Cytomegaloviruses devoted a large part of their genome to encode genes, 
which modulate the host cell behaviour and response to infection. Data from 
sequencing and functional genomic analyses revealed that about 45 to 57 out of 160 
predicted viral genes are dedicated to essential tasks of replication (Mocarski and 
Courcelle, 2001; Dunn et al., 2003a). This involves a number of herpesvirus-common 
genes, identified in all mammalian and avian herpesviruses (Davison et al., 2003). 
The herpesvirus-common genes form seven conserved blocks. Arrangement of the 
conserved blocks is a typical characteristic of the three herpesvirus subfamilies. The 
β-herpesviruses form the most divergent subgroup, as they have unique genome 
organisation. During co-evolution of the virus with its host, duplications of viral genes 
occurred and resulted in gene families. The β-herpesviruses are distinguished by the 
presence of additional gene families; one of them is US22 gene family.  
The US22 gene family is characterised by the presence of four conserved 
sequence motifs. It has been speculated that the conserved motifs preserve essential 
functions for the virus. However, functional analyses have shown that the members 
of this family have quite diverse functions. Some of them were shown to be 
transcription activators (Cardin et al., 1995; Flebbe-Rehwaldt et al., 2000; 
Romanowski and Shenk, 1997), others were found to optimize viral growth in certain 
cell types (Menard et al., 2003; Cavanagh et al., 1996) or have an antiapoptotic 
function (Skalletskaya et al., 2001, Menard et al., 2003). Only four members of the 
family have so far been reported to be essential for the virus replication. These are 
the HCMV genes TRS1 and IRS1 and m142 and m143 of MCMV. It was previously 
shown that deletion of both TRS1 and IRS1 results in a replication-deficient virus 
(Brune et al., unpublished). At the beginning of the project, investigators reported that 
disruption of m142 and m143 results in a replication-incompetent virus (Menard et al., 
2003), but no one had successfully regrown MCMV mutants lacking the genes m142 
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or m143. This work presents the first data on analysis of MCMV mutants where the 
genes m142 or m143 were deleted. The mutants were reconstituted on 
complementing NIH3T3 cells, stably expressing the viral genes m142 or m143. 
Growth analyses confirmed the expectation that m142 and m143 are essential for 
virus replication. The defect of the deletion mutants could not be compensated by 
high MOI infection. However, reinsertion of the corresponding genes into the MCMV 
genome completely restored the wild-type phenotype. Moreover, from the present 
experiments it is clear that m142 and m143 are both required for efficient virus 
replication. An analysis of viral DNA replication showed that the deletion mutant-
infected cells have reduced levels of DNA. Only when the missing gene is reinserted 
and both, m142 and m143 are present, the DNA levels are comparable to the wild-
type virus. Additionally, the inability to reconstitute the double deletion mutant on 
NIH3T3 cells expressing either m142 or m143 confirmed the hypothesis that they 
cannot compensate for each other and most likely have different roles for MCMV 
replication.  
To investigate further the role of m142 and m143 in the MCMV replication 
cycle, gene expression pattern was analyzed. Since it was already reported that 
TRS1 and IRS1 have transcriptional activity in transient transfection assays (Stasiak 
and Mockarski, 1992), it was assumed that m142 and m143 also might be involved in 
regulation of gene transcription. It was shown that the viral proteins, expressed at 
different times in cells infected with deletion mutants are detectable with exception of 
the late proteins. However RNA analyses revealed that late viral transcript levels are 
not changed when m142 or m143 are deleted, excluding a role of these proteins in 
gene transcription. Further characterisation of the proteins in the context of viral 
infection showed that m142 and m143 are predominantly localized in the cytoplasm. 
This finding is in agreement with independently obtained data by Hanson and co-
workers (2005). Although some of the US22 gene products reported to be 
transcriptional transactivators were also detected in the cytoplasm (Mori et al., 1998; 
Romanowski and Shenk, 1997).  
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4.2. The HCMV genes TRS1/IRS1 and MCMV m142 and m143 encode 
proteins with homologous functions 
 
Sequence comparison of HCMV ORFs to m142 and m143 showed that the 
closest sequence homologues are US26 and US23, respectively (Rawlinson et al., 
1996). Both genes were found to influence the virus growth, as the deletion of US26 
or US23 results in attenuated phenotype (Dunn et al., 2003; Yu et al., 2003). 
However neither of them is essential. Screening of the MCMV genome for 
homologues to IRS1 and TRS1 showed that m142 and m143 are the closest. 
Additionally, TRS1 and IRS1 as m142 and m143 are the only members of the family 
which lack the conserved sequence motif II. It was previously shown that deletion of 
both TRS1 and IRS1 results in a growth-deficient virus (Brune et al., unpublished). 
Moreover, the present study demonstrated that TRS1 can substitute for m142 and 
m143, when provided in cis- or trans-position. The deletion mutants could be 
complemented by TRS1, expressed from NIH3T3 cells. As a confirmation, it was 
shown that insertion of TRS1 into the MCMV genome, lacking m142 or m143 
resulted in a replication-competent virus.  
The IRS1 gene, which has 75% sequence homology with TRS1 and share 
sequence from both repeated and unique segments of the genome, was also tested 
for complementation. The N-terminal two thirds of pTRS1 is encoded in the c repeat 
region, and the remainder of the protein is coded within the unique short region. The 
related protein, pIRS1, is encoded in the internal c‘ region together with the adjacent 
unique short region. Consequently, the N-terminal domains of pTRS1 and pIRS1 are 
nearly identical, and the two proteins have different C-terminal domains (Wetso and 
Barrell, 1986). However, insertion of IRS1 into the MCMV lacking m142 or m143 did 
not yield a detectable virus. This result correlates with the reported data that deletion 
of IRS1 has no impact on HCMV replication (Blankenship and Shenk, 2002; Jones 
and Muzithras, 1992), whereas deletion of TRS1 results in attenuated growth 
(Blankenship and Shenk, 2002). The defect of the HCMVΔTRS1 mutant could be due 
to a viral assembly failure (Adamo et al., 2004). The accumulation of viral transcripts 
in infected cells with the TRS1 mutant is comparable to those found in the 
nonattenuated IRS1 mutant (Blankenship and Shenk, 2002). The MCMV genes 
m142 and m143 are both essential for virus replication, whereas TRS1 and IRS1 are 
essential only when deleted together. The present data showed that only TRS1 can 
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rescue the replication of m142 and m143. Moreover the expression of late proteins 
was partially restored by reinsertion of TRS1 into the MCMV deletion mutants, 
suggesting a functional homology. 
Recently it was reported that TRS1 and IRS1 can rescue the replication of a 
vaccinia virus lacking the ds-RNA-binding protein E3L (Child et al., 2002, 2004). 
Later, Hakki and Geballe (2005) proved that TRS1/IRS1 have dsRNA binding activity. 
Other investigators have reported that TRS1 and IRS1 can restore the dsRNA-
dependent-proteinkinase R (PKR) mediated protein synthesis shutoff, induced by a 
recombinant herpes simplex virus type 1 (HSV-1) lacking the γ134.5 gene (Cassady 
2005). The finding that TRS1 is a functional homolog to m142 and m143, suggested 
that the MCMV genes are also involved in prevention of protein synthesis shutoff. 
This possibility was analysed by metabolic labelling of infected cells which showed 
that deletion of m142 or m143 results in reduced protein synthesis. This result led to 
the conclusion that m142 and m143 encode proteins which prevent the shut-down of 
protein synthesis.  
 
4.3. Protein synthesis inhibition by the host cell  
 
The protein synthesis shutoff is one of the mechanisms employed by the host 
cell for limiting viral replication. It is triggered by dsRNA. Virus replication of 
mammalian cells involves the following events, which start with entry, continues with 
RNA expression and processing, polypeptide synthesis and modification, genome 
replication, and maturation. As intracellular parasites, viruses are dependent on the 
cellular machinery and resource to complete their life cycle. The dsRNA structures 
are formed as annealed bi-directional overlapping transcripts from DNA viruses such 
as herpesviruses (Schneider and Mohr, 2003). Additionally, short interfering RNAs 
and micro RNAs are processed from longer dsRNAs or RNAs with hairpins, which 
can mimic dsRNA and contribute to the antiviral response (Li and Ding. 2005; Matzke 
et al., 2002).  
Double-stranded dsRNA is a strong inducer of interferon beta (IFNβ), which 
represents the first defence line of infected cells in response to viral infection. The 
induction of IFNβ is regulated at the level of transcription initiation. The 
cytomegalovirus virion is recognized by Toll-like receptors, and the following signal 
transduction results in activation of IFNβ genes. Produced IFNβ stimulates the 
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neighbouring cells by activating type I IFN receptors. This triggers activation of the 
Jak/STAT pathway, which induces the expression of a broad spectrum of cellular 
genes, named interferon-stimulated genes (ISGs). These genes encode proteins that 
are constitutively expressed at low levels but are upregulated in presence of dsRNA. 
ISGs encode proteins with antiviral activities, one of the best characterized is the 
dsRNA-dependent protein kinase R (PKR).  
PKR is a major player in the innate antiviral immune response. It is a 
multifunctional protein that also regulates apoptosis, cell proliferation, signal 
transduction, and differentiation (Proud, 1995). Overexpression of PKR has been 
suggested to inhibit cell proliferation in yeast, insect, and mammalian cells (Chong et 
al., 1992). In contrast, expression of catalytically inactive mutants of PKR in NIH3T3 
cells results in tumorigenicity in nude mice, which is attributed to a dominant-negative 
effect of mutant PKR (Koromilas et al.,1992). Mouse embryo fibroblasts derived from 
PKR-deficient mice are resistant to cell death induced by dsRNA and 
lipopolysaccharides (Der et al., 1997). PKR has been suggested to be involved in 
dsRNA transduction pathways leading to NF-κB activation and the p38 mitogen-
activated kinase pathway (MAPK) (Goh et al., 2000). In PKR deficient, but not wild-
type cells, dsRNA fails to induce NF-κB activation, which correlates with the lack of 
interferon-β production.  
PKR is one of the key factors in the innate immune response. It is subject to a 
fine regulation. PKR activity is positively regulated by a cellular protein, named PKR-
activating protein (PACT)/RAX (Patel and Sen, 1998). This protein was identified as a 
PKR interacting protein, which activates PKR in absence of dsRNA. PACT is 
expressed under stress conditions, treatment of cells with arsenite, and interleukine-3 
deprivation. This results in phosphorylation of PACT/RAX and association with PKR, 
which is followed by PKR activation and phosphorylation of eIF2α. PKR is also 
subject to a negative regulation by P58. P58 was initially identified as an influenza 
virus-activated protein that interacts with the kinase domain of PKR and inhibits its 
activity. In normal cells, the P58 associates with a heat shock protein 40 and forms 
an inhibitory complex. Cellular stress or virus infection induces dissociation of P58 
from heat shock protein 40. Therefore, the released P58 can bind PKR and disrupt its 
activity. Overexpression of P58 reduces eIF2α phopshorylation, mediated by the 
PKR-like endoplasmatic reticulum kinase (PERK) in mouse embryonic stem cells. In 
general PKR and PERK are activated in response to different stimuli. However, a 
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crosslink exists between the PKR and PERK pathways (Baltzis et al., 2004). In 
response to vesicular stomatitis virus infection, phosphorylation of PKR is reduced in 
PERK deficient MEFs as compared to the wild type cells and the virus replicates 
efficiently. Chemical induction results of PKR phosphorylation in PERK expressing 
MEFs but not in PERK-negative, showing that antiviral action of PERK is mediated by 
PKR. The mechanism of PKR activation by PERK is unknown. Activated PKR 
phosphorylates the translation factor eIF2α, which is responsible for recruitment of 
the small ribosomal subunit during the initial step of protein synthesis. The 
phosphorylated eIF2α cannot be utilized anymore, and therefore protein synthesis is 
inhibited. Translational arrest is an important immune evasion mechanism. To date 
only two genes from human cytomegalovirus have been reported to prevent the PKR- 
mediated protein synthesis shutoff: TRS1 and IRS1. Since the experiments described 
in this work have shown that TRS1 can restore late protein synthesis of the MCMV 
mutants lacking the genes m142 or m143, it was obvious to assume that the genes 
have a similar function. Analysis of infected cells by western blot showed that eIF2α 
is phosphorylated when m142 or m143 are deleted. Moreover detection of PKR in 
deletion-mutant-infected cells resulted in additional bands with shifted mobility. The 
obtained data contributed to the conclusion that m142 and m143 are required to 
prevent the PKR mediated protein synthesis shut-down. The same result was 
observed when cells were treated with the dsRNA homolog poly I:poly C. However, 
whether activation of PKR is due to direct effect of deleted genes or a consequence 
and how PERK is involved is currently unknown. 
This is the first report on US22 gene family members of MCMV involved in 
preventing the PKR-mediated translational arrest. These results correlate with 
unpublished data from Child and co-workers (2006), that m142 and m143 have 
dsRNA binding activity, providing knowledge about the mechanism of action. As it 
was already demonstrated in this study, the MCMV genes m142 and m143 are both 
required for virus replication, it is speculated that they prevent PKR activation in a 
cooperative manner. Up to now the exact mechanism remains unknown. It is possible 
that at least one of the proteins has a dsRNA-binding domain, capable of 
sequestering the dsRNA and preventing PKR from being activated. Alternatively, the 
other protein might prevent autophosphorylation of PKR by direct binding to the 
effector protein or suppressing the upregulation by unknown mechanism, involving 
virus or cellular transcription factors. In this respect the analysis of interaction 
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partners of m142 and m143 should be of great interest for future studies. The 
potential interaction partners could be viral or cellular proteins. 
The prevention of PKR-mediated protein synthesis shut-down was 
demonstrated in this work for m142 and m143, which correlated with previously 
reported results about TRS1. However, the complementation of the deletion mutants 
with TRS1 was only partial, suggesting that these proteins have a multifunctional 
nature and not all functions are shared. For instance, the TRS1 and IRS1 proteins, 
unlike m142 and m143 function as transcriptional transactivators in transient 
transfection assays (Romanowski and Shenk.,1997; Stasiak and Mocarski,1992). 
Other investigations showed that TRS1 but not IRS1 is required for efficient virion 
assembly (Adamo et al., 2004). Up to now it is not known if m142 or m143 are 
involved in this process. 
Considering the multiple function of TRS1, it may appear surprising that it 
could complement for m142 and m143 only partially. The insertion of TRS1 into 
MCMV deletion mutants resulted in replication competent virus only when the HCMV 
gene was expressed from the heterologous PGK promoter. This finding may be 
explained by the fact that m142 and m143 have unusually weak promoters (Hanson 
et al., 2005). Thus, the observed partial functional homology of TRS1 with m142 and 
m143 is most likely due to conservation of herpesvirus common genes and 
differences arising from the adaptation of the specific virus to its host. 
 
4.4. Evasion of the host antiviral response  
 
 PKR activation and subsequent translational inhibition is part of the antiviral 
response. To establish productive infection, viruses have evolved mechanisms to 
overcome the deleterious effect of PKR. The inhibition of PKR pathway is immune 
evasion mechanism, exploited by many viruses. The herpes simplex virus γ134.5 
protein directs the cellular protein phosphatase 1 to dephosphorylate eIF2α, whereas 
poliovirus employs a cellular proteinase to degrade PKR. In addition, viruses employ 
counter measures to inhibit interferon production or signal transduction initiated by 
interferons. Recent studies have shown that cytomegalovirus can perturb the PERK 
pathway (Isler et al., 2005, Tirosh et al., 2005). The phosphorylation of PERK was 
detected at late times during infection. However, eIF2α was phopshorylated only to a 
limited extent and translation of proteins was not impaired, suggesting that the virus 
 77
  Discussion 
affects the downstream eIF2α signalling. Currently no CMV gene product has been 
identified as an inhibitor of PERK activation.  
A number of viruses encode dsRNA binding proteins. For example, the NS1 
protein from Influenza virus (Tan and Katze, 1998) and E3L from vaccinia virus 
(Sharp et al., 1998) bind directly to PKR and inhibit its function. Although the 
influenza virus NS1 protein is critical for its ability to overcome the IFN response, it 
was also reported to induce the activation the cellular inhibitor of PKR, P58 (Lee et 
al., 1990, 1992; Melville et al., 1997). NS1 also regulates the nuclear export of 
cellular mRNAs (Fortes et al., 1994) and affects pre-mRNA maturation by inhibiting 
splicing and polyadenylation-site cleavage (Chen et al., 2002). Another virus that 
regulates the activity of PKR is vaccinia virus. Vaccinia encodes two genes, E3L and 
K3L, both of which determine resistance to interferon (Langland and Jacobs, 2002). 
The E3L protein, synthesized early during infection, contains an amino-terminal Z-
DNA-binding domain and a carboxyl-terminal domain with a dsRNA binding motif 
(Chang et al., 1995). The carboxyl-terminal domain of E3L sequesters the dsRNA 
and prevents the activation of PKR and phopshorylation of eIF2α. E3L deletion 
mutant is highly sensitive to interferon, and the gene is essential for the virus growth 
in mice (Brandt and Jakobs, 2001). The K3L protein has homology to eIF2α and acts 
as a pseudo substrate for PKR in competition with eIF2α. Both proteins act together 
to prevent the phosphorylation of eIF2α and block the host cell protein synthesis 
shutoff.  
E3L was reported to have functional homology with the HCMV genes TRS1 
and IRS1. Each of these genes could rescue the replication of vaccinia virus lacking 
E3L (Child et al., 2004). Other studies have shown that E3L and TRS1 can prevent 
the phosohorylation of eIF2α (Child et al., 2004, Cassady, 2005). Since the present 
work demonstrated that TRS1 can substitute for m142 and m143, it was expected 
that the vaccinia virus E3L gene product could complement the deletion mutants as 
well. However the insertion of E3L into the MCMV deletion mutant genome did not 
result in a replication competent virus. The expression of E3L under control of PGK 
promoter could not rescue the virus replication as well. The inability of the vaccinia 
virus gene to substitute for the MCMV genes could be due to the different nature of 
poxviruses and that E3L and m142/m143 are more distant than TRS1/IRS1. 
However, the MCMV genes m142 and m143 could rescue the replication of a mutant 
vaccinia virus, lacking the E3L gene (Hanson et al., 2006). 
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  4.5. New insights into the MCMV immune evasion mechanisms 
 
Immune evasion mechanisms play a crucial role in virus replication. The innate 
immune response is the first defence line that the virus has to overcome in order to 
complete successfully its replication and assure efficient transmission to a new host. 
CMVs have developed various strategies to modulate the environment in the host 
and facilitate efficient infection. The impacts of immunomodulatory functions, that 
counteract the host immune response, become better understood because many 
herpesviruses, adenoviruses and poxviruses encode similar functions. Human and 
murine cytomegalovirus-encoded proteins modulate many categories of host defence 
and inflammation: classical as well as non-classical major histocompatibility complex 
(MHC) protein function, leukocyte migration, activation and cytokine responses, host 
cell susceptibility to apoptosis, induction and activity of cytokines and interferons, and 
antibody defence mechanisms (reviewed in Mocarski, 2004).  
The present study reports that the MCMV genes m142 and m143 are both 
required to prevent the PKR-mediated protein synthesis shut-down. This represents 
an important mechanism for MCMV to escape the innate immune response and 
executes the essential task for m142 and m143. This is the first data presenting the 
importance of the antiviral protein PKR for murine cytomegalovirus replication. All 
US22 gene family members studied up to now are involved in the innate or adaptive 
immune response. The present work extends the existing knowledge and provides 
new insights into MCMV immune evasion and survival strategies. Table 18 
summarizes the current data about innate immune evasion genes encoded by CMVs 
and the new knowledge obtained from the presented study (Table 18). 
 Immunity type  Immune response HCMV MCMV 
Innate  IFN induction  - -  
 IFN signalling UL27, IE1 M27 
 IFN effectors (PKR) TRS1, IRS1 m142, m143 
 NK cells UL16, UL40, UL18 m144,m152, m155, m157 
 Cytokine UL111a, UL146, US28, 
UL21.5, UL128, UL147, 
UL33, US27 
m131-m129 
 
 
Table. 18. Immune evasion genes encoded by HCMV and MCMV. The genes indicated 
in bold are discussed in the text, the others are reviewed in Mocarski, 2002. 
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In the light of previous data, obtained by other investigators, the results of the 
present work were used to generate a model. The proposed model suggests that the 
MCMV genes m142 and m143 and TRS1/IRS1 of HCMV, can bind dsRNA and 
thereby prevent the autophopshorylation of PKR and subsequent inhibition of protein 
synthesis. As discussed above, the same was shown by other investigators for the 
vaccinia virus protein E3L. Moreover, vaccinia virus possesses an additional gene 
K3L, which binds to PKR and prevents its dimerization, which would result in eIF2α 
activation and subsequent protein synthesis inhibition. Although E3L failed to 
substitute for m142 and m143, it is possible that m142 or m143 act in a similar 
manner. As it was shown by Child and co-workers (unpublished), both proteins m142 
and m143 are required for dsRNA binding. The present data demonstrates that each 
of them is necessary to prevent PKR and eIF2α phopshorylation. This suggests that 
either m142 or m143 may cooperate with PKR to prevent its dimerization and 
subsequent phosphorylation of eIF2α. The other protein might be necessary to 
sequester dsRNA and block the induction of IFNβ. To date, the effect of m142 and 
m143 on IFNβ induction has not been analysed. 
In this respect, testing for possible interaction partners of m142 and m143, 
especially PKR is a promising research perspective. Alternatively, it is possible that 
either m142 or m143 cooperate with factors regulating the PKR activity: P58, heat 
shock protein 40 (HSP40) or PACT. This would explain a potential indirect effect of 
m142 and/or m143 on activation of PKR. The protein P58 forms a complex with 
HSP40, but is released upon stress or infection. The released P58 can bind to PKR 
and thereby inhibit its activation. It was shown that influenza virus can activate P58 
(Lee et al., 1990, 1992). Whether m142 or m143 have similar function remains to be 
determined. PACT is phosphorylated upon infection, which results in association with 
PKR and subsequent activation of the enzyme. Eventual binding of virus-encoded 
proteins to PACT would prevent the activation of PKR. Thus, analysis of possible 
interaction of m142 or m143 with PACT would contribute to understanding the 
mechanism of immune evasion. The present work demonstrated that the MCMV 
genes m142 and m143 are not involved in regulation of viral gene transcription. 
However, it is unclear whether they can influence the transcription of the cellular 
genes in the context of viral infection. As it was shown in the described experiments, 
deletion of m142 and m143 results in activation of PKR. It is known that PKR is an 
effector protein, which expression levels are regulated by activation of ISGs. The 
 80
  Discussion 
activation of PKR is associated with upregulation of the cellular level.  Therefore it is 
considered that m142 or m143 can suppress the upregulation of the PKR expression 
by interacting with transcriptional factors, most likely virus-encoded. Potential 
candidate is the MCMV gene product IE1, which is known to have regulatory function 
(Mocarski et al., 1996, Paulus et al., 2006). Further, analysis of the conserved 
domains responsible for binding with certain cellular or virus-encoded factors would 
reveal the underlying mechanism of immune evasion. 
 
 
 
PKR P-PKR 
Translation arrest 
eIF2α P-eIF2α 
Effector protein 
MCMVHCMV 
dsRNA
Signal cascade 
Virus entry 
ISGs 
m142, m143
TRS1, IRS1
 
 
 Fig. 29. Proposed model for new immune evasion mechanism of CMV. The HCMV 
genes TRS1 and IRS1 as well as the MCMV genes m142 and m143 bind the dsRNA to 
prevent the activation PKR. The products of m142 and m143 interact directly to prevent 
the activation of PKR. It is considered also indirect effect of m142 and m143 on PKR 
activation. These genes may interact with the factors, regulating the PKR activity. PACT 
is a positive regulator and P58 can inhibit the PKR activation after its dissociation from 
the heat shock protein 40 (HSP40). 
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6.1. Abbreviations  
 
 
α- 
μ- 
Δ- 
Alexa Fluor 488/594 
AA/BA 
bp 
BAC 
CPE 
DIG High Prime 
ECL 
E.Coli 
GFP 
gB 
HA-tag 
HRP 
HCMV 
IF 
INF 
ORF 
kD 
LC 
MCMV 
MOI 
MMLV 
Nt 
PAAGE 
PAAG 
PPGK
PCR 
RT PCR 
SAP 
SB  
WB 
Anti   -  (indicating antibody against a protein) 
Mikro -  (μg, μL) 
Delta  -  (indicating deleted sequence) 
Antibody conjugated fluorescent dye emitting at 488/594 nm  
Acrylamide/ bisacrylamide 
Base pairs 
Bacterial artificial chromosome 
Cytopathic effect 
Digogexigenin labeling kit 
Enhanced chemiluminiscence 
Echerichia Coli 
Green fluorescent protein 
Glycoprotein B 
Hemaglutinin tag 
Horse raddish peroxidase 
Human cytomegalovirus 
Immunofluorescence 
Interferon 
Open reading frame 
Kilo Daltons 
Light Cycler 
Murine cytomegalovirus 
Multiplicity of infection 
Moloney Murine Leukemia virus  
Nucleotides 
Polyacril amide gel electrophoresis 
Polyacrylamide gel 
Phosphoglukokinase promoter 
Polymerase chain reaction 
Real time PCR 
Shrimp alkaline phosphatase 
Southern blot 
Western blot 
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6.4. Appendix 1. Maps of constructed plasmids 
 
A. Expression plasmids 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. Retroviral vectors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. Replacement vectors 
 
Appendix 2 
 
ORF 
 
Position 
(bp) 
Published sequence Working sequence 
 
Effect  
m143 201 403 C – C   CGC  13 AA1 shorter protein 
TRS1 227 911 
228 247 
228 437 
226 119 
226 388 
228 437 
228 247 
227 911 
A 
T 
A 
G 
G 
C 
G 
G 
 C 
C 
G 
C 
A 
T 
A 
T 
 Silent 
Gly – Ser 
Val – Leu 
 
 
Silent 
Gly – Ser 
Val – Leu  
IRS1 189 806 T C  Silent  
189 887 A C Silent  
189 996 A G Gly - Ser 
Identified mismatches. Sequences were aligned against HCMV genome lab strain AD169, 
accession number gi 59591 or MCMV Smith strain u68299. 
 98
6.5. Statement / Erklärungen 
 
 
Hiermit erkläre ich ehrenwörtlich, dass ich die Dissertation „Functional analysis of the 
murine cytomegalovirus genes m142 and m143“ selbständig angefertigt und keine 
anderen als die von mir angegebenen Quellen und Hilfsmittel benutzt habe.  
 
Zudem erkläre ich, dass diese Dissertation weder in gleicher noch in anderer Form 
bereits in einem Prüfungsverfahren vorgelegen hat. 
 
Ich habe früher außer den mit dem Zulassungsgesuch urkundlich vorgelegten Graden 
keine weiteren akademischen Grade erworben oder zu erwerben versucht. 
 
 
 
 
 
 
 
 
 
Würzburg den, 
 
 
Ralitsa Stamatova Valchanova 
 
 99
6.6. Curriculum vitae 
 
 
 
Personal data 
 
 
Ralitsa Stamatova Valchanova 
 
Born on 27th January, 1979 in Varna, Bulgaria 
 
Bulgarian  
 
 
 
 
 
Education 
 
 
2002 - 2006 PhD student 
Faculty of Biology, University of Wuerzburg 
Rudolf Virchow Center, Wuerzburg 
Graduate College ‘Target proteins’ 
 
2001  Degree Master of Science
qualification Molecular Biologist  
specialization Clinical Chemistry 
Sofia University ‘’St. Kliment Ohridski’’, Bulgaria 
 
 
1996-2001  Undergraduate student of Molecular Biology
Faculty of Biology 
Sofia University ‘’St. Kliment Ohridski’’, Bulgaria 
 
 
1993-1996  High School  ‘’St. Kliment Ohridski’’,Varna, Bulgaria 
 
 
1986-1993 Elementary School  ‘’St. Kliment Ohridski’’,Varna, Bulgaria 
 
 
 
 100
 
6.7. Publication list 
 
 
 
 
Ralitsa Valchanova,  Marcus Picard-Maureau, and Wolfram Brune. 2006. Murine 
cytomegalovirus m142 and m143 are both required to block protein 2 kinase R-
mediated shut-down of protein synthesis. Submitted to Journal of Virology. 
 
 
 
Poster presentations:  
 
Ralitsa Valchanova, Marcus Picard-Maureau, Wolfram Brune. 2006. Mouse 
Cytomegalovirus genes m142 and m143 counteract the PKR mediated host immune 
response. (Poster presentation at Young Investigator Symposium on Infection, 
Biology, Wuerzburg – Berlin, Berlin, March 2006). 
  
Ralitsa Valchanova, Wolfram Brune. 2005. Functional analysis of murine 
cytomegalovirus genes m142 and m143. (oral presentation at the meeting of 
Graduate colleague ’Target proteins’ RVZ Wuerzburg, Germany). 
 
Ralitsa Valchanova, Wolfram Brune. 2005 Functional homology of mouse 
cytomegalovirus genes m142 and m143 with the human cytomegalovirus gene 
TRS1. (Poster presented at Gesellschaft für Virologie Annual meeting in Hannover, 
Germany). 
 
Ralitsa Valchanova, Wolfram Brune. 2004. Functional analysis of the essential 
immediate-early genes m142 and m143 of murine cytomegalovirus (Poster presented 
at Gesellschaft für Virologie Annual meeting in Tuebingen, Germany). 
 
 
 
 
  
 
 
 
 101
